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In Brief
Control of MRE11 association with
chromatin by UBQLN4 during double-
strand break repair influences repair
pathway choice and can be dysregulated
in tumorigenesis.
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Genomic instability can be a hallmark of both
human genetic disease and cancer. We identify
a deleterious UBQLN4 mutation in families with
an autosomal recessive syndrome reminiscent of
genome instability disorders. UBQLN4 deficiency
leads to increased sensitivity to genotoxic stress
and delayed DNA double-strand break (DSB) repair.
The proteasomal shuttle factor UBQLN4 is phos-
phorylated by ATM and interacts with ubiquitylated
MRE11 to mediate early steps of homologous
recombination-mediated DSB repair (HRR). Loss of
UBQLN4 leads to chromatin retention of MRE11,
promoting non-physiological HRR activity in vitro
and in vivo. Conversely, UBQLN4 overexpression
represses HRR and favors non-homologous end
joining. Moreover, we find UBQLN4 overexpressed
in aggressive tumors. In line with an HRR defect inthese tumors, UBQLN4 overexpression is associated
with PARP1 inhibitor sensitivity. UBQLN4 therefore
curtails HRR activity through removal of MRE11
from damaged chromatin and thus offers a therapeu-
tic window for PARP1 inhibitor treatment in UBQLN4-
overexpressing tumors.
INTRODUCTION
In response to genotoxic stress, cells activate a signaling network,
collectively referred to as the DNA damage response (DDR). The
DDR activates cell-cycle checkpoints, DNA repair pathways,
and, if damage is beyond repair capacity, triggers cell-death path-
ways (Reinhardt and Yaffe, 2013). Following DNA double-strand
breaks (DSBs), the DDR is primarily activated by the proximal ki-
nase ataxia telangiectasia mutated (ATM), which phosphorylates
a plethora of substrates, such as KAP-1, CHK2, p53, MRE11,
RAD50, NBS1, and others (Shiloh and Ziv, 2013).
The main DSB repair pathways are the canonical non-
homologous end joining (c-NHEJ) pathway and homologousCell 176, 505–519, January 24, 2019 ª 2018 Elsevier Inc. 505
recombination repair (HRR). Error-prone c-NHEJ operates
throughout the cell cycle and directly ligates the processed
DSB ends, whereas error-free HRR is restricted to late S and
G2, when a repair template is available (Dietlein et al., 2014).
Additional mutagenic DSB repair pathways are alternative
NHEJ and single-strand annealing (Dietlein et al., 2014). The bal-
ance between these different pathways is essential for correct
DSB repair (Dietlein et al., 2014).
In contrast to thewealth of phosphorylation targets in theDDR,
the number of known ubiquitylation substrates at DSB sites is
small (Harding and Greenberg, 2016). While K63-linked ubiquity-
lation mediates functional alterations of the target protein, K48-
linked ubiquitin chains mark target proteins for proteasome-
mediated degradation (Walczak et al., 2012). Notably, we
previously observed recruitment of proteasomes to DSB sites
(Levy-Barda et al., 2011), raising the possibility that the regulated
turnover of proteins at DSB sites may be critical for a proper DSB
response.
In proteasome-mediated protein degradation, ubiquitylated
proteins are recognized by specific proteasome subunits (Grice
and Nathan, 2016). Additional selectivity is provided by loosely
associated shuttle factors that mediate target recognition by
the proteasome. Three such shuttles were identified in budding
yeast: Dsk2, Rad23, and Ddi1 (Hartmann-Petersen et al., 2003).
Rad23 and Ddi1 have been implicated in the DDR, as Rad23
functions in nucleotide excision repair (Ng et al., 2003), and
Ddi1 is required in the proteasomal degradation of homothallic
switching (HO) endonuclease, which generates a site-specific
DSB at the mating type locus (Kaplun et al., 2005). The
mammalian orthologs of Dsk2 are members of the ubiquilin
family, ubiquilin1–4 (UBQLN1–4) (Hu et al., 2012). Ubiquilins
contain ubiquitin-like (UBL) and ubiquitin-binding (UBA) do-
mains. Their role as shuttles that direct cargo to the protea-
some is mediated by the binding of ubiquitylated proteins
through their UBA domain and simultaneous interaction with
the proteasome subunit s5a through their UBL domain (Ko
et al., 2004).
Here, we identify a homozygous UBQLN4 germline mutation,
p.R326X, in a complex inherited disorder. Affected patients
display characteristics similar to other genome instability syn-
dromes, such as ataxia-telangiectasia and others (Hoeijmakers,
2001). Mechanistically, we show that UBQLN4 is phosphory-
lated in an ATM-dependent manner and recruited to sites of
DNA damage, where it redirects DSB repair toward NHEJ by
functionally repressing HRR. We further show that UBQLN4 in-
teracts with ubiquitylated MRE11, to facilitate its proteasomal
degradation. Moreover, reduced HRR usage in UBQLN4-over-
expressing tumor cells is associated with an actionable PARP1
inhibitor sensitivity.
RESULTS
Identification of the UBQLN4 Deficiency Syndrome
We identified an autosomal recessive syndrome in two consan-
guineous families (Figures 1A and 1B). Two patients (A-IV-4,
B-IV-3) were followed from birth to 10 and 11 years of age,
respectively. Patient A-IV-3 was a stillbirth and was hence not
followed further. These patients displayed intellectual impair-506 Cell 176, 505–519, January 24, 2019ment, growth retardation, microcephaly, facial dysmorphism,
hearing loss, ataxia, and anemia. Moreover, a pregnancy in
family A was terminated at the end of the first trimester due to
polyhydramnios, nuchal translucency, and single umbilical artery
(fetus A-IV-5). A detailed clinical description of the patients is
provided in Figures 1A, 1B, and S2 and Table S1 and the Human
subjects section within the STAR Methods. We performed
whole-exome sequencing of cells isolated from A-IV-4 and
A-IV-5. This analysis revealed a detrimental homozygous
c.976C > T mutation in exon 6 of the UBQLN4 gene in both pa-
tients (Figure S1A; Table S2). This mutation is predicted to
create a premature stop codon (p.R326X) (Figure 1C). Sanger
sequencing confirmed c.976C > T homozygosity in the affected
individuals, while the parents were heterozygous carriers (Fig-
ures 1C and S1B). Of note, out of a total of 8 shared homozygous
variants, the UBQLN4 c.976C > T mutation was the only shared
aberration predicted to be truncating (Figure S1A; Table S2).
To investigate whether the c.976C > T mutation affects
UBQLN4 expression, we performed immunoblots. We analyzed
dermal fibroblasts (DMFs) derived from B-IV-3, A-IV-5, and
B-III-2 using antibodies directed against C- and N-terminal
UBQLN4 epitopes. Neither of these antibodies detected full-
length UBQLN4 in cells from B-IV-3 or A-IV-5, while DMFs
derived from B-III-2 showed reduced UBQLN4 expression,
compared to wild-type (WT) (Figures 1D and S1C). We note
that the N-terminal antibody detected a faint unspecific band
in WT cells below the full-length UBQLN4 band that was also
seen in patient-derived cells (Figure S1C). To rule out the pos-
sibility of a transcript variant that skips the c.976C > T mutation
in exon 6, we performed RNA sequencing (RNA-seq). The ex-
pressed allelic fraction of the p.R326X mutation was 100%
in both patients (Figure 1E). In addition, A-IV-5 and B-IV-3
showed a low-level expression of a novel transcript containing
an exon 5–7 splice junction, omitting exon 6 (Figure 1E). How-
ever, exon 6 skipping leads to a frameshifted transcript, pre-
dicted to contain a downstream stop codon (p.L321X), poten-
tially giving rise to a 321-amino-acid protein, which was not
detected in patient cells (Figure 1D). Of note, patient cells,
and to a lesser extent parent cells, showed on average an
almost 3-fold decrease in UBQLN4 mRNA expression,
compared to WT samples of the same cell type (Figure S1D),
indicating that the mutant transcripts may be subject to
nonsense-mediated mRNA decay. Our data indicate that the
c.976C > T mutation creates a UBQLN4-null allele, leading to
a novel autosomal recessive syndrome in homozygotes, which
we term ‘‘UBQLN4 deficiency syndrome.’’
Loss of UBQLN4 Confers Hypersensitivity to Genotoxic
Agents
We recently conducted an RNAi screen in conjunction with
automated microscopy, using ATM-dependent KAP-1 phos-
phorylation as a readout (Figure S1E) (Baranes-Bachar et al.,
2018). Re-analysis of these experiments revealed sustained
KAP-1 phosphorylation in UBQLN4-depleted cells after treat-
ment with the radiomimetic drug neocarzinostatin (NCS), sug-
gesting delayed DNA repair in the absence of UBQLN4 (Fig-
ure S1F). Thus, we next examined the response of cells
derived from patient B-IV-3 to genotoxic stress. Patient and
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Figure 1. A Homozygous c.976C > T Mutation in the UBQLN4 Gene Leads to UBQLN4 Deficiency Syndrome
(A) Pedigree of UBQLN4 deficiency syndrome in family A.
(B) Pedigree of UBQLN4 deficiency syndrome in family B.
(C) Sequencing of lymphocyte gDNA from a healthy donor (WT), A-IV-4 and his parents. Arrow indicates the c.976C > T mutation. Bottom: domain diagram of
UBQLN4 depicting the N-terminal UBL, C-terminal UBA domain, and 4 middle-region STI1 motifs. The p.R326X mutation is indicated.
(D) Immunoblot detecting UBQLN4 in the DMF lines with an antibody against the C-terminal epitope.
(E) Proportion of splice junction counts per mean coverage of spliced exons and expressed allelic fraction of the c.976C > T mutation obtained from RNA-seq of
A-IV-4, B-IV-3, B-III-2, and 2 WT controls.
See also Figures S1 and S2 and Tables S1 and S2.WT DMFs were treated with NCS, etoposide, cisplatin, or hy-
droxyurea (HU). Consistent with a role of UBQLN4 in the DDR,
UBQLN4 mutant cells exhibited a significantly increased sensi-
tivity to all four genotoxic agents, compared to WT (Figures
2A–2D). Heterozygous cells showed NCS, etoposide, and HUsensitivities, between those of patient and WT cells (Figures
2A, 2B, and 2D). Cisplatin sensitivity was similar in the patient
and heterozygous cells (Figure 2C). Complementation of patient
cells with UBQLN4wt reverted the hypersensitivity to all four gen-
otoxic agents (Figures S3A–S3E). Furthermore, RNAi-mediatedCell 176, 505–519, January 24, 2019 507
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Figure 2. UBQLN4 Loss Increases Cellular Sensitivity to Genotoxic Agents
(A–D) Cells of the indicated genotypeswere treatedwith NCS (A), etoposide (B), cisplatin (C), or HU (D) for 96 hr and viability was assessed by CellTiterGlo assays.
Error bars represent SD of the mean of 3 independent experiments. p values were calculated using t test with Welch’s correction not assuming equal variance.
*p < 0.05, **p < 0.01, ***p < 0.001.
(E–H) Cleaved caspase-3 positivity was assessed by flow cytometry at the indicated time points in U2OS cells transduced with the indicated constructs, after
NCS (500 ng/mL) (E), etoposide (10 mM) (F), cisplatin (20 mM) (G), or HU (20 mM) (H) treatment. Error bars represent SD of the mean of n = 3 experiments.
Significance was determined with paired Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.
(I) Representative images of gH2AX foci 48 hr after HU (20 mM) or mock treatment, using HCS microscopy. DAPI served as a counterstain. Scale bars, 100 mm.
(J–M) Cells of the indicated genotypeswere treated for 2 hr with NCS (500 ng/mL) (J), etoposide (20 mM) (K), cisplatin (20 mM) (L), or HU (20mM) (M) and stained for
gH2AX at the indicated time points. Data were analyzed with R, using ordinary two-way ANOVA. Bonferroni post hoc analysis was applied to determine p values
(legend continued on next page)
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UBQLN4 depletion rendered U2OS cells significantly more sen-
sitive against NCS, compared to controls in clonogenic survival
assays (Figures S3F and S3G). Of note, ATM inhibition with
KU60019 had a slightly more pronounced effect on NCS sensiti-
zation than UBQLN4 depletion (Figures S3F and S3G). Next, we
quantified DNA damage-induced apoptosis in U2OS cells ex-
pressing either two distinct UBQLN4-depleting short hairpin
RNAs (shRNAs), or a control hairpin (Figure S3F). When cells
were treated with NCS, etoposide, cisplatin, or HU, UBQLN4-
depleted cells displayed a significantly increased cleaved-cas-
pase-3 (CC3)-positive population in response to all four geno-
toxic agents, compared to controls (Figures 2E–2H). These
results suggest that loss of UBQLN4 confers hypersensitivity to
DNA-damaging agents and leads to enhanced apoptotic cell
death in response to DNA damage.
UBQLN4 Depletion Results in Impaired DSB Repair
To ask whether UBQLN4 loss of function affects DNA repair
kinetics, we next assessed the accumulation and clearance of
DNA lesions in DMFs following NCS, etoposide, cisplatin, or
HU exposure. We employed automated immunofluorescence
microscopy to quantify nuclear gH2AX foci, as a surrogate for
unrepaired DNA lesions (Figures 2I–2M). In response to NCS
and etoposide, we observed a significantly delayed clearance
of gH2AX foci in patient and heterozygous cells, compared to
WT (Figures 2J and 2K). Of note, UBQLN4 depletion in U2OS
cells resulted in a similarly delayed clearance of NCS-induced
gH2AX foci, compared to controls (Figure S3H). In contrast to
the etoposide and NCS response, cells treated with cisplatin
and HU showed a continuous increase of gH2AX foci throughout
the 48-hr observation period (Figures 2L–2M). In line with defec-
tive DNA repair in UBQLN4-deficient settings, patient and het-
erozygous cells displayed a significantly increased number of
gH2AX foci following cisplatin and HU exposure, compared to
WT (Figures 2L–2M). We observed a massive accumulation
of gH2AX foci in late S-phase, specifically in cisplatin-treated
UBQLN4 mutant cells, compared to WT (Figure S3I). Moreover,
the decrease in cell counts induced by each of the genotoxic
agents was significantly enhanced in patient cells, and to a lesser
extent in heterozygous cells, compared to WT (Figure S3J). In
line with the experiments shown in Figure S3B, re-expression
of ectopic UBQLN4 rescued the number of surviving UBQLN4
mutant cells after NCS treatment (Figure S3K).
To determine the impact of UBQLN4 depletion on the sealing of
NCS-inducedDSBs,weperformedneutral comet assays inU2OS
cells expressing two distinctUBQLN4-targeting shRNAsor a con-
trol shRNA.Of note, alkaline comet assays do not differentiate be-
tween single-strand break and DSB, whereas the neutral comet
assay specifically reports DSBs (Olive and Bana´th, 2006). The
comet assays revealed a substantial DSB repair defect in
UBQLN4-depleted cells,which could be rescued upon re-expres-
sion of shRNA-resistant UBQLN4wt (Figures 2N and S3L–S3M).of selected pairs defined in a contrast matrix using the R library multcomp. Error b
Each experiment was carried out twice. *p < 0.05.
(N) Quantification of the relative comet tail moment (n = 100) derived from the ne
mean of the relative comet tail moment analyzed in n = 3 experiments. Significance
See also Figure S3.UBQLN4 Is Recruited to Sites of DNA Damage
To ask whether UBQLN4 relocates to sites of DNA lesions, we
induced focal DNA damage by micro-laser irradiation of single
nuclei in U2OS cells. Using an UBQLN4-specific antibody (Fig-
ures S3N and S3O), we noticed that UBQLN4 was recruited to
these sites, where it co-localized with 53BP1 (Figure 3A). To
further characterize the kinetics of this UBQLN4 recruitment,
we expressed ectopic GFP.UBQLN4 in U2OS cells and moni-
tored its recruitment to laser-induced damage. A fraction of
GFP.UBQLN4 was recruited to the damage sites within 5 min
of damage induction (Figure 3B). We also employed biochemical
fractionation to demonstrate enrichment of UBQLN4 in the chro-
matin fraction after NCS exposure (Figure S4A). To assess
whether the UBL or UBA domains of UBQLN4 were required
for this recruitment, we generated UBQLN4 deletion mutants
(Figure S4B) and found that neither the UBL nor the UBA domain
was required for recruitment to sites of laser-induced damage
(Figure S4C).
ATM-Dependent UBQLN4 Phosphorylation Is Required
for a Proper Cellular DDR
A phosphoproteomic screen previously detected a peptide that
represented phosphorylation of UBQLN4 on S318 in response to
ionizing radiation (IR) (Matsuoka et al., 2007). Importantly, S318
is located in a highly conserved S-S-Q-P amino acid sequence
that contains the potential ATM substrate motif, S318-Q (Rein-
hardt and Yaffe, 2013) (Figure 3C). We therefore aimed to vali-
date this finding and to further characterize the regulation and
functional significance of this phosphorylation. We raised a
polyclonal, phospho-specific antibody against pS318/UBQLN4
and assessed its specificity in anti-GFP immunoprecipitates
from IR-treated U2OS cells overexpressing GFP.UBQLN4 or
a non-phosphorylatable GFP.UBQLN4S318A mutant. The anti-
pS318 UBQLN4 signal was enhanced following IR in UBQLN4wt,
compared to GFP.UBQLN4S318A precipitates (Figures S4D and
S4E). When we inspected the anti-GFP precipitates on SDS-
PAGE, we also detected endogenous UBQLN4, indicating the
formation of homo-dimers or -polymers, an observation that
we confirmed in co-immunoprecipitation experiments (Figures
S4D and S4F). The signal obtained with the anti-pS318 antibody
in immunoblotting of lysates from irradiated cells was reduced
when the cells were UBQLN4 depleted (Figure S4G). Notably,
pS318/UBQLN4 was induced by several genotoxic agents,
including IR, etoposide, camptothecin, and HU (Figures S4H
and S4I). Moreover, pS318/UBQLN4 was detected primarily in
the nuclear and particularly the chromatin fraction, whereas
only faint signals were obtained in cytoplasmic and membrane
fractions (Figure S4J). Longitudinal monitoring revealed that
pS318/UBQLN4 peaked within 30 min after IR and subsided
4–6 hr later (Figure 3D). These kinetics are similar to that of
ATM-mediated KAP-1 phosphorylation (Figure 3D). As the S-Q
motif can similarly be phosphorylated by other kinases, suchars represent SD of the mean for 3 replicate wells analyzed in one experiment.
utral comet assays at the indicated time points. Error bars represent SD of the
was determined with paired Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.
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as ataxia telangiectasia- and Rad3-related (ATR) and DNA
dependent protein kinase (DNA-PK) (Reinhardt and Yaffe,
2013), we employed small-molecule inhibitors to examine their
role in this phosphorylation. Consistent with an ATM dominance
in mediating S318/UBQLN4 phosphorylation, the ATM inhibitor,
KU60019, abolished NCS-induced pS318/UBQLN4. The ATR in-
hibitor, AZ20, appeared to delay this phosphorylation, whereas
the DNA-PK inhibitor, KU60648, had no apparent effect on
S318 phosphorylation (Figures 3E and S4K). We validated the
ATM dependence of the S318 phosphorylation in a phospho-
mass spectrometry experiment (Figure 3F; Table S3). We
treated FLAG.UBQLN4-expressing U2OS cells with NCS (1 hr,
500 ng/mL) or vehicle. To assess the role of ATM in UBQLN4
phosphorylation, we also included cells that were treated with
KU60019 30 min prior to addition of NCS. We found 1,400
NCS-induced phosphorylation sites, of which 522 were less
abundant in the presence of KU60019 (Table S3). Importantly,
NCS treatment induced S318 phosphorylation, which was
almost completely abolished in the presence of KU60019 (Fig-
ure 3F). Of note, the pS144/UBQLN4 site displayed a similar
ATM-dependent and NCS-induced phosphorylation pattern
(Figure S4L), indicating that UBQLN4 is also targeted by ki-
nase(s), selecting proline-directed motifs.
To ask whether UBQLN4 phosphorylation impacts on sensi-
tivity to genotoxic stress, we used clonogenic survival assays
in U2OS cells (Figures 3G and S4M). UBQLN4 depletion resulted
in marked NCS sensitivity, compared to control cells (Figure 3G).
This phenotype could be fully rescued by ectopic expression of
UBQLN4wt, whereas UBQLN4S318A failed to rescue the UBQLN4
depletion phenotype, similar to UBQLN4 mutant proteins
lacking either the UBL or UBA domain (Figures 3G, S4N, and
S4O). We next tested whether UBQLN4 phosphorylation inter-
feres with the sealing of NCS-induced DSBs, using a neutral
comet assay carried out in the cell clones used in Figure 3G,
as well as a UBQLN4-depleted clone that was complemented
with a phospho-mimicking S318D mutant (Figure S4P). Here,
UBQLN4 depletion significantly delayed DSB sealing, compared
to cells expressing control shRNA or UBQLN4-depleted cells
that were complemented with either WT or UBQLN4S318D (Fig-
ures 3H and S4Q). UBQLN4-depleted cells complementedFigure 3. The ATM Target UBQLN4 Localizes to Sites of DNA Damage
(A) Recruitment of endogenous UBQLN4 to sites of laser-induced damage. Cells w
green line (left panel) indicates the location of laser-induced damage. Scale bar,
(B) Dynamics of UBQLN4-recruitment to laser-inducedDNA damage. Cells were d
with GFP or UBQLN4.GFP. Scale bar, 10 mm.
(C) Sequence alignment within UBQLN4 exon 6 depicting inter-species conserv
mutation.
(D) Immunoblot displaying the time course of the S318 UBQLN4 phosphorylation
(E) UBQLN4 phosphorylation is ATM mediated. U2OS cells were treated with
subsequent immunoblotting. Arrows indicate pS318/UBQLN4 bands. ATMi, KU6
(F) Selected LC-MS/MS scan of the pS318/UBQLN4 peptide and annotated b- an
group. Inset top right: LC-MS/MS measured intensities of the pS318 site after in
(G) Clonogenic survival assay of U2OS cells transfected with the indicated constr
shUBQLN4 or pre-treated with KU60019 served as controls. Error bars represent
with Welch’s correction not assuming equal variance. *p < 0.05.
(H) Quantification of the relative comet tail moment on the indicated cells (n = 100
bars represent SD of the mean of the relative comet tail moment analyzed in n
*p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S4 and Table S3.with UBQLN4S318A displayed a comet tail moment that was
indistinguishable from that observed in UBQLN4-depleted cells
(Figures 3H and S4Q). These results suggest that UBQLN4 phos-
phorylation on S318 is functionally important for its role in the
DSB response.
Loss of UBQLN4 Leads to Increased HRR
Mammalian cells employ two major DSB repair pathways,
namely, NHEJ and HRR (Dietlein et al., 2014). Particularly
HRR is dependent on ATM activity (Dietlein et al., 2014). Here,
we showed that UBQLN4 is an ATM substrate and that DSB
sealing is markedly impaired in UBQLN4-depleted cells. HRR
depends on a 50-30 DSB end resection, which is initiated
by the MRE11 nuclease (Symington and Gautier, 2011). As
UBQLN4 is a proteasome shuttling factor (Ko et al., 2004), we
next pursued a candidate approach to ask whether UBQLN4 in-
teracts with HRR proteins. We treated GFP- and GFP.UBQLN4-
expressing U2OS cells with vehicle solution or NCS and
performed anti-GFP pull-downs, which revealed that MRE11
co-precipitated with GFP.UBQLN4, particularly after NCS
exposure (Figure S5A). These data suggest that MRE11 is one
of probably many UBQLN4 interaction partners. Based on this
observation, we hypothesized that UBQLN4 might direct DSB
repair pathway choice. Thus, we used two distinct assays to
assess the differential use of HRR and NHEJ in UBQLN4-
depleted and UBQLN4-overexpressing U2OS cells. Using the
SeeSaw reporter system (Lo´pez-Saavedra et al., 2016) to quan-
tify the relative use of HRR and NHEJ, we found that UBQLN4
depletion significantly increased the relative contribution of
HRR over NHEJ in DSB repair, whereas UBQLN4 overexpres-
sion significantly increased the relative use of NHEJ (Figures
4A and S5B). Of note, expression of UBQLN4S318A failed to pro-
mote NHEJ (Figure 4A).
We corroborated these data using the DR-GFP reporter (Lo´-
pez-Saavedra et al., 2016) (Figure S5C). Similar to the SeeSaw
system, the DR-GFP assay demonstrated significantly increased
HRR usage in UBQLN4-depleted cells, compared to controls
(Figure 4B). UBQLN4-overexpressing cells showed significantly
decreased HRR usage, whereas expression of UBQLN4S318A
had no detectable impact on HRR usage (Figure 4B).ere laser microirradiated and stained 15min later for UBQLN4 and 53BP1. The
10 mm.
epleted of endogenous UBQLN4 (30 UTR-targeting shRNA) and complemented
ation. Asterisk indicates Homo sapiens S318. Triangle indicates the p.R326X
in U2OS cells after 10 Gy IR.
the indicated inhibitors 30 min prior to NCS (500 ng/mL, 1 hr) exposure and
0019 (5 mM); DNA-PKi, KU60648 (10 mM); ATRi, AZ20 (0.5 mM).
d y-ions. Fragment ions marked with asterisk result from loss of the phospho-
dicated treatments.
ucts and treated with the indicated NCS concentrations. Cells transfected with
SD of the mean of n = 3 experiments. p values were calculated using the t test
) was assessed, using an automated COMET analysis software package. Error
= 3 experiments. Significance was determined with paired Student’s t test.
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Figure 4. Loss of UBQLN4 Leads to Increased HRR
(A) Effect of UBQLN4 small interfering RNA (siRNA), FLAG.UBQLN4 or FLAG.UBQLN4S318A overexpression on the NHEJ:HRR ratio in the SeeSaw reporter
assay. CTIP-depleting siRNAs served as a positive control. Irrelevant siRNA and FLAG plasmid served as controls. An NHEJ:HRR ratio >1.0 represents a
shift toward NHEJ. The data represent 4 sets of triplicate experiments. Error bars represent SEM. A paired t test was used for statistical analysis. *p < 0.05,
**p < 0.01.
(legend continued on next page)
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We validated these findings in vivo, by assessing the role of
C. elegans ubql-1, the nematode ortholog of UBQLN4, in HRR.
During the first hours of embryogenesis, C. elegans selectively
employs HRR to repair DSBs (Lemmens and Tijsterman, 2011).
IR of early WT C. elegans embryos led to a dose-dependent sur-
vival reduction, which was significantly alleviated in the ubql-1
mutant (Figure 4C). These data imply an evolutionarily conserved
role for UBQLN4 in DSB repair.
Our data may suggest a model in which UBQLN4 regulates
DSB repair pathway choice by repressing HRR through removal
of HRR factors from the damaged site. We tested this model by
comparing the NCS-induced spatial dynamics of several HRR
factors inUBQLN4mutant andWT cells. We longitudinally moni-
tored RPA70 and RAD51 foci (indicators of ongoing HRR), as
well as 53BP1 foci (indicating NHEJ activity) (Dietlein et al.,
2014) and observed a significantly increased number of RPA70
and RAD51 foci in patient cells, compared to WT (Figures
4D and 4E). This difference was particularly obvious in S-phase
and G2/M cells (Figures 4D and 4E). In contrast, 53BP1 foci
were significantly reduced in NCS-treated patient cells,
compared to controls (Figure 4F), supporting a role of UBQLN4
in curtailing HRR. To rule out a net effect of the different amounts
of DNA lesions in the different genotypes (Figure 2J), we normal-
ized the number of RPA70 and 53BP1 foci against amounts of
gH2AX foci (representing unrepaired DSBs) (Figures S5D and
S5E). The results indicated that the increased RPA70 and
decreased 53BP1 foci in UBQLN4 mutant cells were not the
result of an increased number of unrepaired DNA lesions per
se (Figures S5D and S5E).
UBQLN4 Is Required for MRE11 Turnover in the
Chromatin
We showed that the DSB resection-initiating nuclease MRE11
interacts with UBQLN4 in response to NCS (Figure S5A). To
scrutinize the role of the UBQLN4:MRE11 interaction for DSB
repair, we examined the effect of UBQLN4 depletion on
MRE11 retention in the damaged chromatin (Figures S5F and(B) Cells harboring a single copy of DR-GFPwere transfected with the indicated si
and FLAGplasmid served as controls. siRNA against CTIPwas used as a positive
SEM. A paired t test was used for statistical analysis. *p < 0.05, **p < 0.01, ***p <
(C) C. elegans ubql-1(tm1574)mutants display improved embryonic survival upon
The brc-1 mutant strain served as an HRR-defective control. brc-1(tm1145) em
periments. Error bars represent SD of the mean. A paired t test was used for sta
(D–F) RPA70- (D), RAD51- (E), and 53BP1 nuclear foci (F) were quantified accord
way ANOVA. Bonferroni post hoc analysis was applied to determine p values of se
represent the SD of the mean of 3 replicate wells analyzed in one experiment. Eac
test, *p < 0.05.
(G) Representative images ofMRE11- and ubiquitin (Ub) nuclear foci, using quanti
served as a counterstain. Overlay images were generated between MRE11 and
(H and I) Cells of the indicated genotypes were treated with NCS (500 ng/mL) and
points. 2,500 cells/well were counted at each time point, and Ub fluorescence was
mean ± SEM, two-way ANOVA with Bonferroni post hoc test, *p < 0.05.
(J) The overlap area (in%) of MRE11 and Ub foci was calculated by overlay of nuc
experiments with 2 replicate wells each, mean ± SEM, two-way ANOVA with Bo
(K) ubql-1(tm1574) mutants display elevated levels of ubiquitinated proteins in th
Scale bar, 10 mm.
(L) For quantification of (K), five germlines per genotype and condition were score
analysis. *p < 0.05.
See also Figure S5.S5G). We carried out cycloheximide chase experiments in
conjunction with NCS treatment in WT and UBQLN4 mutant
cells. These experiments revealed a significantly increased
accumulation of MRE11 in the chromatin fraction of UBQLN4
mutant cells, compared to WT, 6 hr after NCS treatment (Figures
S5F and S5G). This observation was validated using longitudinal
immunofluorescence. As shown in Figures 4G and 4H, MRE11
nuclear foci were significantly increased in UBQLN4 mutant
DMFs 6–48 hr after NCS treatment, compared to WT and
UBQLN4wt-complemented patient cells. Of note, the cell-cycle
distribution of untreated and NCS-exposed WT, UBQLN4
mutant, and UBQLN4wt-complemented patient cells showed
only mild differences (Figure S5H). Specifically, WT cells showed
slightly increased S-phase and G2 populations, compared to
UBQLN4 mutant cells (Figure S5H), which, if anything, should
lead to an underestimation of the increased HRR in UBQLN4
mutant cells.
To ask whether UBQLN4-deficient cells accumulate ubiqui-
tylated proteins at DNA damage sites, we performed immuno-
fluorescence with the FK2 antibody, to detect mono- and
polyubiquitylated proteins. UBQLN4 mutant cells showed
increased numbers of FK2-positive nuclear foci after NCS
exposure, compared to WT or patient cells complemented
with UBQLN4wt (Figures 4G and 4I). Pre-treatment with the
proteasome inhibitor MG132 led to similar amounts of NCS-
induced FK2 foci in patient and WT cells (Figure S5I), indi-
cating that the NCS-induced FK2 foci in patient cells result pri-
marily from inefficient proteasomal clearance of ubiquitylated
proteins from damage sites. Intriguingly, the overlap area of
MRE11 and FK2 foci was markedly increased in patient cells,
compared to WT and UBQLN4-complemented patient cells,
potentially indicating that MRE11 is ubiquitylated itself and ac-
cumulates at DSB sites in patient cells (Figures 4G and 4J).
We obtained similar data in ubql-1 mutant C. elegans. IR treat-
ment induced massive accumulation of FK2 foci after 24 hr in
the distal germline of ubql-1 mutant worms, compared to WT
animals (Figures 4K and 4L).RNAs or FLAG plasmids and gene conversion was assessed. Non-target siRNA
control. The data represent 4 sets of triplicate experiments. Error bars represent
0.001.
IR (40 Gy), compared to N2WT, indicative of an elevated HRR repair capacity.
bryos showed increased lethality after IR. The data represent 3 replicate ex-
tistical analysis. *p < 0.05.
ing to cell-cycle stage. Experiments were analyzed with R, using ordinary two-
lected pairs defined in a contrast matrix using the R librarymultcomp. Error bars
h experiment was carried out twice. Two-way ANOVA with Bonferroni post hoc
tative HCSmicroscopy for untreated andNCS-treated (500 ng/mL) DMFs. DAPI
Ub stainings for indicated genotypes. Scale bar, 10 mm.
stained for nuclear MRE11- (H) and ubiquitin (Ub) foci (I) at the indicated time
quantified, as in (D)–(F). n = 3 replicate experiments with 2 replicate wells each,
lear foci data generated in (H) and (I) for the indicated genotypes. n = 3 replicate
nferroni post hoc test, *p < 0.05.
e distal germline upon IR, as shown by increased numbers of FK2 stained foci.
d. Error bars represent SD of the mean. A paired t test was used for statistical
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Figure 5. MRE11 Inhibition Represses the Non-physiological HRR in UBQLN4 Mutant Cells
(A) Immunoblot of various GFP-tagged UBQLN4 proteins that co-precipitated with FLAG.MRE11. Immune complexes were obtained from lysates of 293FT cells
mock-treated or treated with NCS (500 ng/mL, 1 hr). USP2 (50 nM) was added to the precipitates (30 min at 37C).
(B) Immunoblot of endogenous UBQLN4 immunoprecipitation or respective IgG control in 293FT cells treated with NCS (500 ng/mL, 1 hr). USP2 (50 nM) was
added as in (A).
(C) Immunoblot of various GFP-tagged UBQLN4 proteins that co-precipitated with FLAG.MRE11. Immune complexes were obtained from lysates of 293FT cells
mock-treated or treated with NCS (500 ng/mL, 1 hr).
(D) SMART analysis of U2OS cell expressing the indicated constructs. The length of individual fibers was measured and the median of at least 250 fibers
was calculated. The average of the medians and the SD of 5 independent experiments are shown. Significance was determined with the paired Student’s t test.
*p < 0.05, **p < 0.01.
(E and F) Cells of the indicated genotypes were pre-treatedwithMirin (100 or 500 mM) (E), PFM01 (200 or 500 mM) (F), or DMSO1 hr prior to NCS (500 ng/mL, 10 hr)
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See also Figure S5.To assess whether MRE11 was ubiquitylated after NCS treat-
ment, we expressed HIS.Ubiquitin and either FLAG.MRE11 or
empty vector in HEK293FT cells. Anti-HIS immunoprecipitation
revealed NCS-induced co-precipitation of FLAG.MRE11, sug-
gesting that MRE11 was ubiquitylated following DNA damage
(Figure S5J). To ask whether UBQLN4 interacted with MRE11
in a ubiquitylation-dependent fashion, we co-expressed
FLAG.MRE11 and GFP.UBQLN4 and immunoprecipitated GFP
after NCS exposure. FLAG.MRE11 efficiently co-precipitated
with GFP.UBQLN4, but not with a GFP control (Figure S5K).
Importantly, the FLAG.MRE11:GFP.UBQLN4 interaction was
repressed by pre-treatment of the lysates with the deubiquity-
lating protease USP2 (Figure S5K).
To address whether the interaction between MRE11 and
UBQLN4 was dependent on the C-terminal ubiquitin-interacting
UBA in UBQLN4, we co-expressed FLAG.MRE11 and either
GFP.UBQLN4 or GFP.UBQLN4 lacking the UBA domain
(GFP.UBQLN4DUBA) in HEK293FT cells. While GFP.UBQLN4514 Cell 176, 505–519, January 24, 2019efficiently co-precipitated with anti-FLAG immunoprecipitates,
UBQLN4DUBA could not be detected in these precipitates (Fig-
ure 5A). We confirmed these data using endogenous immuno-
precipitations from NCS-treated HEK293FT cells (Figure 5B).
Intriguingly, while FLAG.MRE11 displayed a robust co-precipita-
tion with GFP.UBQLN4wt, this interaction was massively
reduced when we expressed GFP.UBQLN4S318A, indicating
that this interaction was dependent on ATM-mediated S318/
UBQLN4 phosphorylation (Figure 5C). Together, our data pro-
vide evidence for a model in which, following DSB induction,
UBQLN4 interacts with MRE11 in a ubiquitylation-dependent
manner, in order to remove MRE11 from the site of genotoxic
damage. In line with a proteasome-dependent turnover of nu-
clear MRE11, we find that NCS-treated UBQLN4 mutant cells
display significantly increased nuclear ubiquitin and MRE11
staining, compared to WT (Figures S5L–S5N). Importantly,
following proteasome inhibition with MG132 for 48 hr, the
levels of nuclear ubiquitin and MRE11 staining were similar in
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Figure 6. Overexpression of UBQLN4 Is Associated with PARP1 Inhibitor Sensitivity
(A) Number of nuclear gH2AX foci in GFP- or UBQLN4.GFP-expressing U2OS cells after NCS treatment (50 ng/mL) at indicated times. Error bars represent the SD
of 1000 cells analyzed in 3 experiments. Statistical significance was determined with paired Student’s t test. *p < 0.05. Right-top panel: immunoblot depicting
endogenous and ectopic UBQLN4.
(B) Representative images of neutral comet assays of NCS-induced (50 ng/mL) DSBs in GFP- or UBQLN4.GFP-expressing U2OS cells. Scale bar, 10 mm.
(C) Quantification of the data shown in (B). 100 comet tails were assessed per condition. Error bars represent the SD of the mean of the relative comet tail moment
analyzed in 3 experiments. Significance was determined with paired Student’s t test. *p < 0.05, **p < 0.01.
(D) Clonogenic survival assay of GFP- or UBQLN4.GFP-transduced U2OS cells following NCS exposure. Error bars represent the SD of the mean of n = 3
experiments. p values were calculated using the t test with Welch’s correction not assuming equal variance. *p < 0.05.
(E) Immunofluorescence images of FLAG- or UBQLN4.FLAG-transduced U2OS cells treated NCS (500 ng/mL, 24 hr) and stained for UBQLN4 and cleaved-
caspase 3 (CC3). Scale bar, 10 mm.
(F) Quantification of CC3-positive cells of the above-mentioned experimental setup. Error bars represent the SD of 1,000 cells analyzed in 3 experiments.
Statistical significance was determined with paired Student’s t test. *p < 0.05, **p < 0.01.
(G) UBQLN4 expression levels in 498 neuroblastoma cases classified between stages 1 and 4S according to the International Neuroblastoma Staging
System (INSS).
(H) UBQLN4 expression levels in 498 neuroblastoma cases, classified according to the International Neuroblastoma Risk Group (INRG) staging system into non-
high-risk and high-risk neuroblastomas. Samples were reviewed by a pathologist to ensure a minimal tumor content of 60%.
(I) 498 neuroblastoma cases where divided according to UBQLN4 expression levels into quartiles according to UBQLN4 expression level: high (n = 125), in-
termediate (n = 117), low (n = 128), and very low (n = 128) expression. Kaplan-Meier curves show overall survival.
(J) GIMEN cells were stably transfected with empty-vector or FLAG.UBQLN4 and treated with olaparib (96 hr), before intracellular ATP levels weremeasured, as a
surrogate for viability. Error bars represent the SD of the mean of 3 experiments. p values were calculated using the t test with Welch’s correction not assuming
equal variance. *p < 0.05, **p < 0.01, ***p < 0.001.
(legend continued on next page)
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UBQLN4-proficient and -deficient cells (Figures S5M and S5N),
suggesting that UBQLN4 controls the proteasome-dependent
nuclear MRE11 turnover.
Fitting with a role of MRE11 in initiating DSB end resection, we
showed that UBQLN4 mutant cells, which display aberrant
MRE11 retention at sites of DNA damage, show increased
numbers of RPA70 and RAD51 nuclear foci, following NCS-
induced DNA damage (Figures 4D, 4E, 4G, and 4H). This obser-
vation may reflect an increased number of DSBs that are being
resected. To verify that the increased number of RPA70 foci in
UBQLN4-deficient cells was due to increased resection initia-
tion, rather than enhanced resection processivity, we used the
single-molecule analysis of resection track (SMART) resection
assay (Cruz-Garcı´a et al., 2014). This assay reports resection
processivity at breaks, in which resection has been initiated,
without considering the number of breaks. These experiments
revealed that neither UBQLN4 depletion, nor overexpression of
FLAG.UBQLN4 or FLAG.UBQLN4S318 affect resection proces-
sivity (Figure 5D). Our results thus indicate that UBQLN4 deple-
tion leads to increased MRE11-dependent initiation of end-
resection and subsequent shifting of more DSBs toward HRR.
To verify MRE11 as a functionally relevant UBQLN4 sub-
strate, we next asked whether MRE11 inhibition with exo- (Mirin)
and endonuclease (PFM01) inhibitors overcomes the relatively
increased HRR activity in UBQLN4-defective cells. Pre-treat-
ment with Mirin and PFM01 led to a significant inhibition of
NCS-induced nuclear RAD51 foci in WT and UBQLN4 mutant
cells (Figures 5E and 5F). In conclusion, our mechanistic data
indicate that MRE11 serves a checkpoint function in licensing
the HRR process, which is tightly controlled by UBQLN4.
UBQLN4 Overexpression Protects from Genotoxic
Stress
Given that UBQLN4 overexpression results in a relative increase
of NHEJ over HRR (Figure 4A) and an absolute decrease of HRR
(Figure 4B), we asked whether overall DSB repair capacity may
be affected in cells overexpressing UBQLN4. To this end, we
assessed DNA repair capacity through immunofluorescence
detection of NCS-induced gH2AX foci in U2OS expressing
GFP or GFP.UBQLN4. UBQLN4 overexpression resulted in
significantly faster clearance of gH2AX foci, starting 12 hr after
the initial insult (Figure 6A). Moreover, neutral comet assays
demonstrated that cells expressing UBQLN4.GFP sealed NCS-
induced DSBs significantly more efficiently than control cells
(Figures 6B and 6C). This effect was particularly obvious 12 hr
after NCS application. Furthermore, clonogenic survival assays
revealed that UBQLN4 overexpression protected cells from the
cytotoxic effect of NCS (Figure 6D). Lastly, UBQLN4-overex-(K) SY5Y cells were transduced with control shRNA or 2 shRNAs againstUBQLN4
Error bars represent the SD of themean of 3 experiments. p valueswere calculated
**p < 0.01, ***p < 0.001.
(L) Neuroblastoma cell lines were treated with olaparib (96 hr) and and viability w
iments. Cells were grouped in UBQLN4 low (expression below median) or UBQL
Whitney U test.
(M) Bar chart of the cells reported in (L). Cells are sorted according to their relative
dark gray are cells with IC50 above the median.
See also Figure S6.
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of apoptosis) 24 hr after exposure to high-dose NCS, compared
to controls (Figures 6E and 6F).
High-Level UBQLN4 Expression Is Associated with an
Actionable PARP1 Inhibitor Sensitivity
To assess the relevance of UBQLN4 expression in human can-
cer, we examined 498 neuroblastoma cases (Zhang et al.,
2015). UBQLN4 mRNA expression was significantly increased
in stage 3 and 4 neuroblastomas, compared to stage 1 disease
(Figure 6G). We further found that UBQLN4 mRNA levels were
significantly increased in high-risk cases (n = 176), compared
to non-high-risk patients (n = 318) (Figure 6H). Moreover, high-
levelUBQLN4 expression (quartile of patients with highUBQLN4
expression, n = 125) was associated with reduced event-free
survival (EFS) and overall survival (OS), compared to patients
displaying intermediate, low or very low UBQLN4 expression
(n = 117, n = 128, n = 128, respectively) (Figures S6A and 6I).
We next assessed UBQLN4mRNA levels in breast (n = 5,143),
lung (n = 2,437), and ovarian cancer (n = 1,816), using publicly
available data (Sza´sz et al., 2016). Again, high UBQLN4 expres-
sion was significantly correlated with reduced OS in these co-
horts (Figures S6B–S6D). Further study of the TCGA database
(Cancer Genome Atlas Network, 2015) revealed that high
UBQLN4 expression in melanoma (mRNA Z score R2) also re-
sults in inferior disease-free survival (DFS) and OS, compared
to patients with normal UBQLN4 expression (mRNA Z score <2
and >2) (Figures S6E and S6F). Moreover, in metastatic mela-
noma, high UBQLN4 expression correlated with reduced DFS
and OS, compared to patients with low UBQLN4 expression
(Figures S6G and S6H). We further performed immunohisto-
chemistry on melanoma specimens, which were derived from
nevus (n = 5), primary melanoma (PRM; n = 8), lymph node
metastasized (LNM; n = 10), and distant organ metastasized
(DOM; n = 10) samples. UBQLN4 levels were higher in metasta-
sized (DOM, LNM) than in nevus samples (Figures S6I–S6J).
Thus, our data derived from distinct entities indicate that high-
level UBQLN4 expression is enriched in high-risk and/or
advanced tumors and is associated with reduced OS.
Given that HRR deficiency is associated with sensitivity to
PARP1 inhibitors (Dietlein et al., 2014), we profiled olaparib sensi-
tivity in UBQLN4-overexpressing U2OS cells and isogenic con-
trols. UBQLN4 overexpression significantly increased olaparib
sensitivity (Figure S6K). We further tested the sensitivity of neuro-
blastoma cell lines expressing high (SY5Y) or low (GIMEN)
UBQLN4 levels and found that SY5Y cells displayed significantly
enhanced olaparib sensitivity, compared to GIMEN cells (Figures
S6L and S6M). To substantiate the role of UBQLN4 in mediatingand treated with olaparib (96 hr). Viability was assessed by CellTiterGlo assays.
using the t test withWelch’s correction not assuming equal variance. *p < 0.05,
as assessed by CellTiterGlo assays. IC50 values were determined in 3 exper-
N4 high (expression above median). p value was calculated using the Mann-
UBQLN4 expression. In light gray are cells with IC50 below the median, and in
olaparib sensitivity, we depletedUBQLN4 in SY5Y cells and over-
expressed UBQLN4 in GIMEN cells (Figures S6N and S6O). As
shown in Figures 6J and 6K, UBQLN4 overexpression in GIMEN
cells significantly increased olaparib sensitivity,whereasUBQLN4
depletion in SY5Y cells significantly increased their olaparib resis-
tance.Ofnote, neitherSY5YnorGIMENcells areMYCNamplified.
To test whether high-level UBQLN4 retains its predictive value in
MYCN-amplified cells, we examined olaparib sensitivity in NMB
and SKNDZ neuroblastoma cell lines, which display high- and
low-level UBQLN4 expression, respectively (Harenza et al.,
2017) (Figure S6P). Increased olaparib sensitivity was preserved
in NMB cells, whereas SKNDZ cells were more resistant (Fig-
ure S6Q). We next assessed the olaparib response in a panel of
12 additional neuroblastoma cell lines and found that cells ex-
pressing high UBQLN4 levels showed a significantly increased
olaparib sensitivity, compared to cells with low expression (Fig-
ures 6L and 6M). These data indicate that elevatedUBQLN4 levels
are associated with PARP1 inhibitor sensitivity.
DISCUSSION
The UBQLN4 deficiency syndrome described here is character-
ized by clinical symptoms frequently detected in genome insta-
bility syndromes (Hoeijmakers, 2001). Here, we demonstrated
that UBQLN4 deficiency led to marked cellular sensitivity to gen-
otoxic stress, that UBQLN4 was recruited to sites of DNA dam-
age, and that it was an ATM substrate in the DDR. Importantly,
the ATM-mediated phosphorylation was functionally significant
for the role of UBQLN4 in the DDR.
Mechanistically, we showed that UBQLN4 impacted on DSB
repair pathway choice. It has recently become evident that main-
tenance of the exquisite balance between these pathways is crit-
ical for timely DSB repair and genome maintenance (Baranes-
Bachar et al., 2018). We found that the NHEJ:HRR ratio in
UBQLN4-depleted cells was skewed toward HRR, while ectopic
UBQLN4 overexpression resulted in a relative increase in NHEJ-
driven DSB sealing over HRR. These observations were further
confirmed in C. elegans, where ubql-1 mutants displayed
increased HRR proficiency. Importantly, UBQLN4 overexpres-
sion resulted in an absolute decrease in HRR usage. Further
mechanistic insight into these effects came from the observation
that the apical HRR regulator MRE11 was retained at sites of
DSBs in UBQLN4-deficient cells. We further revealed that
MRE11 was ubiquitylated following DNA damage and demon-
strated that UBQLN4 specifically interacted with ubiquitylated
MRE11 in response to DNA damage. Moreover, this interaction
depended on the UBA domain of UBQLN4, as well as ATM-
mediated S318/UBQLN4 phosphorylation. Finally, we showed
that excessive RAD51 foci formation following NCS treatment
in UBQLN4-deficient cells could be reverted to normal levels,
when the endo- or exonuclease activities of MRE11 were phar-
macologically inhibited. Based on our data, it is tempting to
speculate that a potential function of UBQLN4 within the DDR
is to assist in the timely removal of DDR factors, such as
MRE11, from damaged chromatin, in order to prevent inappro-
priate DSB end resection and subsequent HRR. However, we
note that our data do not exclude the possibility that UBQLN4
has additional interaction partners within and outside of theDDR. A dose-dependent role for UBQLN4 in promoting the use
of NHEJ is supported by the DSB repair reporter assays. The
relative increase in NHEJ usage in UBQLN4-overexpressing
cells may be driven by the functional repression of HRR through
the removal of HRR factors, such as MRE11, from damaged
chromatin. Thus, when the UBQLN4 level is altered in either
direction, the NHEJ:HRR ratio is markedly affected.
Our data suggest a primarily nuclear role of UBQLN4. How-
ever, UBQLN4 does not contain an obvious nuclear localization
sequence. In line with this, we also find a fraction of UBQLN4
localized in the cytoplasm (Figures S3N and S4J). Moreover,
UBQLN1, which shares 71% amino acid sequence homology
with UBQLN4, is involved in triaging incorrectly targeted mem-
brane proteins in the cytosol to a ubiquitin ligase to promote
degradation (Itakura et al., 2016). Thus, it is conceivable that
UBQLN4 is relocated to the nucleus following decoration with
a yet unidentified post-translational modification.
We foundacorrelationbetweenpoorOSandelevatedUBQLN4
expression inneuroblastoma,melanoma,andovarian,breast, and
lung cancer. Our data indicate that UBQLN4 overexpression may
be a selected event in different cancer entities.Weprovide a ratio-
nale for this observation by showing thatUBQLN4overexpression
in cultured cells enhances DSB sealing, reduces apoptosis, and
increases survival, following NCS treatment. It is conceivable
that UBQLN4 overexpression is selected in cancer cells, since it
facilitates effective coping with endogenous DSBs, such as those
occurring during replicative stress. While this largely NHEJ-medi-
ated,moreeffectiveDSBsealing inUBQLN4-overexpressingcells
protects them from acute genotoxic stress, it is likely to be highly
mutagenic, as NHEJ is an error-prone mechanism (Dietlein et al.,
2014). Thus, NHEJ-driven mutagenesis may also be selected for
in cancer cells, since it further promotes genome instability and
oncogenic transformation.
Defective HRR in the context of BRCA1 or BRCA2 loss-of-
function mutations is associated with PARP1 inhibitor sensitivity
(Dietlein et al., 2014). Consistent with an HRR defect inUBQLN4-
overexpressing cells, we found that cells with high UBQLN4
expression were significantly more sensitive to olaparib than
cells with low UBQLN4 expression. It was recently proposed
that NHEJ promotes genomic instability and cytotoxicity in
HRR-deficient cells treated with PARP1 inhibitors (Patel et al.,
2011). In extrapolation of these data, the enhanced NHEJ
observed in UBQLN4-overexpressing cells may contribute to
the toxicity inflicted by PARP1 inhibitors in these cells.
Altogether, our data reveal the biology of a new genome insta-
bility syndrome, provide evidence of a role for UBQLN4 in regu-
lating DSB repair pathway choice, and identify UBQLN4 overex-
pression as a predictor of poor survival in various cancer entities
that is associated with an actionable sensitivity to PARP1
inhibitors.STAR+METHODS
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Antibodies
Mouse anti-UBQLN4, clone A333 Santa Cruz Biotechnology Cat#: sc-136145; RRID: AB_2009286
Rabbit anti-UBQLN4 Lifespan Biosciences Cat#: LS-C108556; RRID:AB_10635383
Rabbit anti-UBQLN4 Bethyl Cat#: A300-BL20642; RRID: N/A
Rabbit anti-phospho-UBQLN4(S318) Bethyl Cat#: A300-BL20645; RRID: N/A
Mouse anti-phospho-Histone H2A.X (Ser139),
clone JBW301
Millipore Cat#: 05-636; RRID: AB_309864
Rabbit anti-RAD51 Millipore Cat#: PC130; RRID: AB_2238184
Mouse a-Tubulin, clone TUB-1A2 Abcam Cat#: ab11325; RRID: AB_2210526
Mouse anti-53BP1 Millipore Cat#: MAB3802; RRID: AB_11212586
Mouse anti-ubiquitinylated proteins, clone FK2 Millipore Cat#: 04-263; RRID: AB_612093
Mouse anti-Flag Santa Cruz Biotechnology Cat#: sc-166355; RRID: AB_2017593
Mouse anti-HSP90, clone 68 BD Biosciences Cat#: 610418; RRID: AB_397798
Mouse b-Actin, clone AC-74 Sigma-Aldrich Cat#: A5316; RRID: AB_476743
Rabbit anti-phospho-KAP1(S824) Bethyl Cat#: A300-767A; RRID: AB_669740
Rabbit anti-MRE11 Novus Cat#: NB 100-142; RRID: AB_350079
Rabbit anti-Histone H3 Abcam Cat#: ab1791; RRID: AB_302613
Mouse anti-His GenScript Cat#: A00186, RRID: AB_914704
Mouse IgG Santa Cruz Biotechnology Cat#: sc-2025; RRID: AB_737182
Rabbit anti-Caspase 3, Active Form BD Biosciences Cat#: 559565; RRID: AB_397274
Anti-BrdU GE Healthcare Cat#: RPN202; RRID: AB_2314032
Goat Alexa Fluor 488 anti-mouse Invitrogen Cat#: A-11001; RRID: AB_2534069
Goat Alexa Fluor 647 anti-mouse Invitrogen Cat#: A-21235; RRID: AB_2535804
Goat Alexa Fluor 488 anti-rabbit Invitrogen Cat#: A-11008; RRID: AB_143165
Goat Alexa Fluor 647 anti-rabbit Invitrogen Cat#: A27040; RRID: AB_2536101
Goat anti-rabbit IgG peroxidase EMD Millipore Cat#: AP132P; RRID: AB_90264
Goat anti-mouse IgG peroxidase EMD Millipore Cat#: 12-349; RRID: AB_390192
Bacterial and Virus Strains
E. coli stable competent (high efficiency) New England Biolabs Cat#: C3040I
Chemicals, Peptides, and Recombinant Proteins
Neocarzinostatin Sigma-Aldrich Cat#: N9162
DNA-PK Inhibitor KU60648 Selleck Chemicals Cat#: S8045
ATM Inhibitor KU60019 Selleck Chemicals Cat#: S1570
Etoposide Hexal N/A
Cisplatin Accord N/A
Hydroxyurea Sigma-Aldrich Cat#: H8627
Camptothecin Millipore Cat#: 208925
USP2 BostonBiochem Cat#: E-504
ATR Inhibitor AZ20 Selleck Chemicals Cat#: S7050
Mirin Sigma-Aldrich Cat#: M9948
PFM01 Sigma-Aldrich Cat#: SML1735
PARP1 Inhibitor olaparib MedChem Express Cat#: HY-10162/CS-0075
MG132 Selleck Chemicals Cat#: S2619
ProLong Gold Antifade Reagent Molecular Probes Cat#: P-36931
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CellTiter-Glo Reagent Promega Cat#: G7573
N-Ethylmaleimide (NEM) Sigma-Aldrich Cat#: E3876
Puromycin Sigma-Aldrich Cat#: P8833
G418 Sigma-Aldrich Cat#: G418-RO
Polybrene Sigma Aldrich H9268-10G
LysC Wako Cat#: 125-05061
GluC Promega Cat#: V1651
Trypsin Promega V5113
Dharmafect-1 Dharmacon T-2001-01
Critical Commercial Assays
Subcellular Protein Fractionation Kit Thermo Fisher 78840
TruSeq Sample Preparation Kit v2 Illumina FC-121-2001
TiO2 Phosphopeptide Enrichment Kit Thermo Fisher A32993
SeqCap EZ Exome v3.0 Kit Roche 06465692001
Agilent DNA 1000 kit Agilent 5067-1504
QuickChange II Site-Directed Mutagenesis Kit Agilent 200523
Deposited Data
Quantative high-content (HCS) microscopy raw
and analyzed data
This paper, Mendeley data https://doi.org/10.17632/gz4xvwbvhs.1
Phospho-proteomic mass-spectrometry raw
and analyzed data
This paper, ProteomeXChange
Consortium, dataset identifier:
PXD011488
https://www.ebi.ac.uk/pride/archive/login
Username:
reviewer13154@ebi.ac.uk
Password:
8Mob4SuW
Experimental Models: Cell Lines
Human Dermal Fibroblasts Patient A-IV-4 isolated from patient N/A
Human Dermal Fibroblasts Patient A-IV-5 isolated from patient N/A
Human Dermal Fibroblasts Patient B-IV-3 isolated from patient N/A
Human Dermal Fibroblasts Parent B-III-2 isolated from patient N/A
Human Dermal Fibroblasts WT_1 isolated from patient N/A
Human Dermal Fibroblasts WT_2 isolated from patient N/A
U2-OS ATCC HTB-96
HEK293FT ThermoFisher Scientific R70007
U2-OS-SSR-GFP Huertas Lab, Sevilla, Spain N/A
U2-OS-DR-GFP Huertas Lab, Sevilla, Spain N/A
MDA-231-MB UBQLN4 CRISPR KO This paper N/A
CHP212 Fischer Lab, Cologne, Germany
(confirmation DSMZ 2007)
CRL-2273 (ATCC)
Kelly Fischer Lab, Cologne, Germany
(confirmation DSMZ 2007)
ACC 355
BE(2)C Witt/Deubzer Lab, Essen,
Germany
CRL-2268 (ATCC)
Lan5 DSMZ 2013 ACC 673
IMR32 DSMZ 2006 ACC 165
Lan-1 DSMZ 2013 ACC 635
CHP134 DSMZ 2013 ACC 653
SHEP Fischer Lab, Cologne, Germany N/A
SK-N-SH ATCC 2014 HTB-11
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SKNAS Fischer Lab, Cologne, Germany
(confirmation DSMZ 2007)
CRL-2137 (ATCC)
CLB-GA Schulte Lab, Essen, Germany
(confirmation DSMZ 2014)
N/A
NBL-S DSMZ 2014 ACC 656
SY5Y Fischer Lab, Cologne, Germany
(confirmation DSMZ 2007)
ACC 209 (DSMZ)
GIMEN DSMZ 2014 ACC 654
SKNDZ ATCC 2014 CRL-2149
NMB DSMZ 2013 ACC 657
Experimental Models: Organisms/Strains
C. elegans: strain N2 Bristol Caenorhabditis Genetics Center WB Strain: N2; C. elegans wild isolate
C. elegans: strain FX1574: ubql-1(tm1574) I. National BioResource Project
(NBRP) SHIGEN Mitani
NBRP Strain: FX1574; WormBase: WBVar00250560;
http://shigen.nig.ac.jp/shigen/index.jsp
C. elegans: strain DW102: brc-1 (tm1145) III. Caenorhabditis Genetics Center WB Strain: DW102; Wormbase: DW102
Oligonucleotides
siRNA targeting sequence UBQLN4 pool Dharmacon Cat#: L-021178-01
siRNA CTIP Huertas Lab N/A
siRNA non-targeted (Ctrl) Huertas Lab N/A
shRNA (pLKO.1) UBQLN4 #1 Sigma-Aldrich Cat#: SHCLNG-NM_020131; TRCN0000007738
CCGGCCAGAGGAAATTCGTGTGAAACTC
GAGTTTCACACGAATTTCCTCTGGTTTTT
shRNA (pLKO.1) UBQLN4 #2 Sigma-Aldrich Cat#: SHCLNG-NM_020131; TRCN0000007741
CCGGGCTGCTCAGATGATGGTGAATCTC
GAGATTCACCATCATCTGAGCAGCTTTTT
shRNA (pLKO.1) non-targeted (Ctrl) Sigma-Aldrich Cat#: SHC016
Recombinant DNA
UBQLN4 cDNA cloned in pCDNA3.1 Gift from Vivian Su N/A
GFP.UBQLN4 cloned in plncx2 This paper N/A
GFP.UBQLN4.S318A in plncx2 This paper N/A
GFP.UBQLN4.S318D in plncx2 This paper N/A
GFP.UBQLN4-dUBA in plncx2 This paper N/A
GFP.UBQLN4-dUBL in plncx2 This paper N/A
GFP in plncx2 This paper N/A
3xFLAG.UBQLN4 cloned in pBabe.puro This paper N/A
3xFLAG.UBQLN4 in pBabe.puro This paper N/A
3xFLAG.UBQLN4-S318A in pBabe.puro This paper N/A
3xFLAG in pBabe.puro Gift from Ron Prywes N/A
FLAG.MRE11 cloned in pCDNA3.1 This paper N/A
HIS.Ub cloned in pCDNA3.1 Gift from Aart G. Jochemsen N/A
pMDLg/pRRE Dull et al., 1998 Addgene Plasmid #12251
pMD2.G Dull et al., 1998 Addgene Plasmid #12259
pRSV-Rev Dull et al., 1998 Addgene Plasmid #12253
pCMV-VSV-G Stewart et al., 2003 Addgene Plasmid #8454
Software and Algorithms
ImageJ software with the PZfociEZ plugin Wayne Rasband (NIH) https://imagej.nih.gov/ij/
Comet Score software TriTek http://rexhoover.com
R v3.4.3 The R Foundation https://www.r-project.org
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NIS ELEMENTS Nikon https://www.nikoninstruments.com/
Adobe Photoshop CS4 (DNA fiber analysis) Adobe https://www.adobe.com/
Adobe Illustrator Adobe https://www.adobe.com/
MaxQuant v1.5.3.8 Cox et al., 2011 http://www.coxdocs.org/doku.php?id=maxquant:
common:download_and_installation#download_
and_installation_guide
Cellomics software package (Colocalization
V.4 Bioapplication)
Thermo Scientific https://www.thermofisher.com/de/de/home/life-
science/cell-analysis/cellular-imaging/high-content-
screening/high-content-screening-instruments/
hcs-studio-2.html
PRISM Graphpad https://www.graphpad.com
Kaluza Beckman Coulter https://www.beckman.com/coulter-flow-cytometers/
software/kaluza
Python v3.6.5 Python Software Foundation https://www.python.org
GATK v3.7 Broad Institute https://software.broadinstitute.org/gatk
BWA v0.7.15 SourceForge http://bio-bwa.sourceforge.net
Annovar v2016.02.01 N/A http://annovar.openbioinformatics.org/en/latest/
Other
CometAssay system Trevigen 4250-050-K
Glass Bottom dishes 35mm MatTek P35G-0-10-C
FLAG M2 beads Sigma-Aldrich M8823
HIS Ni-NTA beads QIAGEN 36111
GFP-trap beads Chromotek gtma-20
MagneTM Protein A Beads Promega G878ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, H. Chris-
tian Reinhardt (christian.reinhardt@uk-koeln.de). The raw whole-exome sequencing data that support the findings in patients cannot
be made publicly available for confidentiality reasons. Qualified researchers may apply for access to the sequencing raw data,
pending institutional review board approval.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects
Written informed consent was obtained from the UBQLN4 deficiency syndrome families for participation in this study. The study was
performed according to theDeclaration of Helsinki protocols andwas approved by the local institutional review board in Essen (ethics
vote 12-5089-BO for CRANIRARE). All subjects were not involved in previous procedures.
Patient A-IV-4 - c.f. Figure 1A, Figures S2A–S2M
Pregnancy was complicated by nuchal edema and polyhydramnios. Birth occurred at 35 weeks of gestation with a weight of
1960 g (- 1.5 SD), a length of 47 cm (0.3 SD) and occipitofrontal circumference (OFC) of 33 cm (mean). The patient had a respiratory
failure that required mechanical ventilation. At birth, he exhibited hypertelorism, microphthalmia, micrognathia, dysplastic and low-
set ears with overfolded helices, a right-sided preaxial polydactyly, and bilateral simian creases (Figures S2B–S2F). Re-examination
at the age of 5 4/12 years revealed low body measurements [weight: 11 kg (5.5 SD), length: 102 cm (2.5 SD), OFC: 47.5 cm
(3.4 SD)]. He was able to crawl, but not walk without support. Deafness and a cryptorchidism were noted as well as proptosis,
downward slanting palpebral fissures, and dysplastic ears (Figures S2G–S2I). At 11 years of age all body measurements were low
[height: 116 cm (4.1 SD), weight: 16 kg (10.9 SD) and OFC: 48 cm (4.8 SD)]. The facial dysmorphisms remained (Figures
S2J–S2L) and dry skin and prominent veins were noted, especially on the forehead and chest. A sleep disorder was reported
by the mother, as well as abnormal feeding behavior with constant craving for food, notable in view of the low weight gain. No
abnormal reaction to sunlight was reported other than light-sensitive eyes. Blood count showed anemia with a hemoglobin ofCell 176, 505–519.e1–e10, January 24, 2019 e4
10.5 g/dl (reference: 11.8-14.9 g/dl), MCV of 76.0 fl (reference: 77-95 fl), MCHC of 30.7 g Hb/dl (reference: 31-39 g Hb/dl). Neurolog-
ical examination revealed spasticity of the lower extremities with brisk reflexes and contractures of both knees. The patient was able
to walk independently, presenting insecure circumduction gait pattern. The upper extremities showed slightly increasedmuscle tone
with almost normal function of small hand muscles. Muscle tone of the trunk was reduced. Cranial nerve examination revealed no
anomalies apart from esotropia and saccadic eye movements. Speech development was markedly retarded, but he was still able
to produce double syllables. The patient presented stereotypic autistic gestures such as body rocking and head nodding,
and self-biting and pinching was reported by the mother. Exome sequencing revealed the homozygous mutation chr1:g.156,044,
148G > A [GRCh38/hg38]; c.976C > T (GenBank: NM_020131.4); p.(Arg326Ter) (NP_064516.2) in the UBQLN4 gene.
Patient B-IV-3 - c.f. Figure 1B, Figures S2N–S2W
Pregnancy was complicated by nuchal edema and oligohydramnios. Birth occurred at 38 weeks of gestation with: [weight: 1970 g
(- 3.0 SD), length: 46 cm (2.2 SD) and OFC: 33.5 cm (- 1.0 SD)]. At 7 weeks of age, proptosis, large nose, small mouth and micro-
gnathia were noted. At the age of 1 3/12 years low anthropometric measures were observed: [weight: 7500 g (2.8 SD), length: 75 cm
(1.8 SD), OFC: 46 cm (1.7 SD)]. The patient was unable to crawl or sit and did not speak. Deafness was diagnosed as well as
hypotelorism, brachycephaly, cryptorchidism, hypoplastic nails, and abnormal semicircular canals. At the age of 6 1/12 years anthro-
pometric measures were low: [height: 100 cm (3.8 SD), weight: 15 kg (3.2 SD) and OFC: 50 cm (1.7 SD)], and the patient was
unable to walk or speak. Proptosis, large nose, short philtrum, camptodactyly of fingers IV/V, contractures of both knees and crypt-
orchidism were observed (Figures S2P–S2R). Recurrent respiratory tract infections reported. At the age of 10 2/12 years, body mea-
surements were: [height: 117 cm (3.7 SD), weight: 16.9 kg (5.6 SD) and OFC: 50.5 cm (2.4 SD)]. Facial dysmorphisms did not
change, and hirsutism, prominent scalp veins, dry skin and three very dark nevi on the soles were observed (Figures S2S–S2W).
Sleep disturbances were reported as well as abnormal feeding behavior with constant craving for food. There was no abnormal re-
action to sunlight. Microcytic-hypochromic anemia was identified. Neurological examination revealed spasticity of the lower extrem-
ities with contractures of the knees. The patient was unable to walk independently. The upper extremities showed slightly increased
muscle tone with almost normal function of small hand muscles, and reduced muscle tone of the trunk. Cranial nerve examination
revealed difficulties initiating pursuit eye movements but the nerve was otherwise normal. There was no progress in speech
development. Stereotypic autistic behavior (repetitive noise making, teeth grinding) was observed. Exome sequencing revealed
the homozygous mutation chr1:g.156,044,148G > A [GRCh38/hg38]; c.976C > T (GenBank: NM_020131.4); p.(Arg326Ter)
(NP_064516.2) in the UBQLN4 gene.
Patients A-IV-3 and A-IV-5 -c.f. Figure 1A
Further clinical information regarding patient A-IV-3 and A-IV-5 can be found in Table S1.
C. elegans strains and maintenance
All worms (age: day 1 of adulthood; sex: hermaphrodites) were grown and maintained at 20C on nematode growth medium (NGM)
agar plates seeded with the E. coli strain OP50 as food source. The Bristol strain N2 was used as wt. Strain DW102 brc-1(tm1145)
served as positive control for the HRR assay. The FX1574 ubql-1(tm1574) strain was obtained from the Shared Information of Genetic
Resources (SHIGEN; http://shigen.nig.ac.jp/shigen/index.jsp) Center of Genetic Resource Information, National Institute of
Genetics, Mishima, Japan, and the presence of the (tm1574) allele was confirmed via genotyping PCR. All strains were backcrossed
4 generations to ancestral N2 and had an uncompromised health status. Worms were not involved in previous procedures and
test naive.
Cell culture, chemical treatment and radiation
Human dermal fibroblast (HDF) lines were established from skin biopsies and authenticated by validating the UBQLN4 c.976C > T
mutation. Sex of HDF cell lines: patient A-IV-4male; patient A-IV-5 female; patient B-IV-3male; parent B-III-2male;WT_1male;WT_2
female. HDFs as well as U2-OS (sex: female), MDA-MB-231 (sex: female) and HEK293FT (sex: female) cells were grown in DMEM
with 10% fetal bovine serum at 37C in 5% CO2 atmosphere. Neuroblastoma cell lines CHP212 (sex: male), Kelly (sex: female),
BE(2)C (sex: male), Lan5 (sex: male), IMR32 (sex: male), Lan-1 (sex: male), CHP134 (sex: male), SHEP (sex: female), SKNAS (sex:
female), CLB-GA (sex: male), SY5Y (sex: female) and GIMEN (sex: female) were grown in RPMI-1640. Neuroblastoma cell lines
SKNDZ (sex: female) and NMB (sex: female) were grown in DMEM; SK-N-SH (sex: female) was grown in Modified Eagle Medium
(MEM, ThermoFisher Scientific, Waltham MA, USA) and NBL-S (sex: male) was grown in Iscove’s Modified Dulbecco’s Medium
(IMDM, ThermoFisher Scientific, Waltham MA, USA). Medium for all neuroblastoma cell lines contained 10% fetal bovine serum
and cells were grown at 37C and 5%CO2. All commercially available cell lines were not further authenticated. The DNA-PK inhibitor,
KU60648, the ATM inhibitor, KU60019, the ATR inhibitor AZ20, the PARP1 inhibitor olaparib and the MRE11 inhibitors Mirin and
PFM01 were diluted in DMSO prior to addition to the culture medium. Cells were irradiated using an X-ray instrument (model
160HF, Philips, Germany), or treated with NCS, hydroxyurea, cisplatin, camptothecin or etoposide.e5 Cell 176, 505–519.e1–e10, January 24, 2019
METHOD DETAILS
Whole-exome sequencing
Genomic DNAwas extracted from peripheral blood using standardmethods. For library preparation, 1 mg of DNAwas fragmented by
adaptive focused acoustics on a Covaris S220 (Covaris Inc, Woburn, MA, USA) for 60 s with a duty cycle of 10%, intensity of 5, and
200 cycles per burst. Library was generated on fragmented DNA using TruSeq Sample Preparation Kit v2 (Illumina) following low-
throughput and gel-free method protocols. Exome enrichment of library fragments was performed with the NimbleGen Human
SeqCap EZ v3.0 Kit (Roche, CA, USA) following themanufacturer’s protocol and under consideration of the technical note ‘‘Targeted
sequencing with NimbleGen SeqCap EZ Libraries and Illumina TrueSeq DNA samples Prep Kit’’ released by NimbleGen. All samples
were analyzed on a Bioanalyzer using the Agilent DNA 1000 kit (Agilent, CA, USA) prior to sequencing on an Illumina HiSeq2000 plat-
form using the paired-end sequencing protocol. 100 bp paired end reads were aligned to the human reference genome (GRCh38/
hg38) using the Burrows-Wheeler Aligner (BWA 0.7.15) and PCR-duplicatemarking was performedwith Picard (v. 1.84). Indel realign-
ment, base quality recalibration and variant calling were performed using the Genome Analysis ToolKit (GATK 3.7) and annotation
with Annovar (version 2016-02-01 using the RefSeq gene definitions and the frequency of the variants in the following databases:
ExAC (Exome Aggregation Consortium, v. 0.3), gnomAD (genome Aggregation Database, v. 2.0), Kaviar (Known VARiants, v.
160204-Public), hrcr1 (halotype reference consortium), and gme (Great Middle East). Variants with a frequency in any database
of > 1% or present in our inhouse database in more than two distinct phenotypes were excluded. Variants further than 10 bp
form the exon/intron boundaries and exonic variants not predicted to affect protein sequence were also excluded. Finally, variants
not present in both datasets, heterozygous variants and hemizygous variants were also excluded.
RNA sequencing
Libraries were prepared using the Illumina TruSeq stranded mRNA sample preparation Kit. Starting with 1 mg of total RNA, poly-A
selection (using poly-T oligo-attached magnetic beads) followed, and mRNA was purified and fragmented using divalent cations un-
der elevated temperature. RNA fragments underwent reverse transcription using random primers followed by second strand cDNA
synthesis using DNA Polymerase I and RNase H. After end repair and A-tailing, indexing adapters were ligated. The products were
purified and amplified (14 PCR cycles) to create the final cDNA libraries. After library validation and quantification (Agilent Tape Sta-
tion), equimolar amounts of the libraries were pooled. The pool was quantified using the Peqlab KAPA Library Quantification Kit and
the Applied Biosystems 7900HT Sequence Detection System. The pool was sequenced in an Illumina HiSeq 4000 sequencer with a
paired-end (2x75nt) protocol. Raw sequencing reads weremapped to the reference genome (hg19) using the Star aligner, and FPKM
expression values were computed based on the refSeq reference transcriptome. Splice junctions between exon 5 and 7 of UBQLN4
were extracted from the alignments (spliced reads) and normalized to the coverage of the corresponding exons. Finally, the relative
proportion of the splice junctions of exon 5-6, 6-7, and 5-7 were determined.
Vector constructs
Full-length UBQLN4 cDNA cloned in pCDNA3.1 was received from Vivian Su (University of Hawaii at Maona), PCR amplified, and
cloned into pLNCX2 (Clontech, Mountain View, CA) using MluI and NotI restriction sites. FLAG or eGFP were PCR amplified and
cloned n-terminal using BglII andMluI restriction sites. GFP.UBQLN4.S318Amutant cDNAwas generated by introducing a point mu-
tation (T952G) and GFP.UBQLN4.S318D mutant cDNA was generated by introducing two point mutations (T952G, C953A) utilizing
the QuickChange II Site-Directed Mutagenesis Kit (Agilent, CA, USA). The GFP.UBQLN4DUBL construct was obtained by deleting
the N-terminal 89 amino acid residues from the protein. The GFP.UBQLN4DUBA construct was obtained by deleting the C-terminal
44 amino acid residues from the protein.
Retroviral and lentiviral vector production
HEK293FT cells were plated into 10 cm dishes in DMEM + 10% FCS, and 24 hr later were co-transfected with pMDLg/pRRE and
pMD2.G packaging plasmids and pLNCX2 expression plasmids encoding various UBQLN4 constructs or empty vector using
CaCl2 transfection. Briefly, cells were seeded to a confluency of 50%–70%. 500 ml 250 mM CaCl2 solution were added into an
Eppendorf tube as well as 10 mg of vector. Afterward, 500 ml 2x HEBS buffer were added dropwise while vortexing the solution thor-
oughly. The solution was then added dropwise onto the cells. The next day, mediumwas changed to DMEM + 20% FCS. Cell culture
supernatants were collected 24, 48 and 72 hr later, centrifuged at 300 g for 5 min and sterile filtered. Using these viral supernatants,
HDFs or U2-OS cells were transduced in the presence of 8 mg/ml polybrene for 24 hr and subsequently selectedwith G418. For RNAi-
mediated gene silencing, replication-incompetent lentiviruses were produced with pLKO.1-Puro based vectors, which expressed
specific shRNAs targeting UBQLN4. For that purpose, HEK293FT cells were co-transfected with pRSV-Rev, pMDLg/pRRE and
pCMV-VSV-G packaging and envelope plasmids and pLKO.1 expression plasmids. Supernatants were collected after 24, 48 and
72 hr, centrifuged at 300 g for 5 min and sterile filtered. U2-OS cells were transduced with these viral supernatants in the presence
8 mg/ml polybrene for 72 hr (3 cycles of transfection) and selected using puromycin. Finally, knockdown efficiency was confirmed by
immunoblotting.Cell 176, 505–519.e1–e10, January 24, 2019 e6
RNA Interference
Cells were grown to 50% confluence and transfected with respective siRNA (UBQLN4, CTIP, Control) using DharmaFECT1 transfec-
tion reagent (Dharmacon Inc.). For that purpose, diluted siRNA (tube 1) and DharmaFECT1 transfection reagent (tube 2) were added
to separate tubes containing serum-free medium and incubated for 5 min at room temperature. Subsequently, contents of tube 1
were added to tube 2 and incubated for 20 min at room temperature and distributed onto respective cell culture dishes. Cells
were then incubated at 37C in 5% CO2 for 48-96 hours for further downstream experiments.
Generation of CRISPR-Cas9 knockout cell lines
Specific CRISPR guides were designed for DNA sequences within exon 1 (CGATCGAGCCTCGGTCAAGG) and exon 6 (AGAAGGG
ATTGTTGCCAAAC) of the UBQLN4 gene using MIT web tool for CRISPR guide selection (http://zlab.bio/guide-design-resources).
The sequences for specific and non-targeting crRNA and trRNA were dissolved in 10 mM Tris-HCl, pH7.4. Thirty to fifty thousand
cells of MDA-MB-231-Cas9 were plated and transfected using 50 nM of each crRNA and trRNA (GE Healthcare Dharmacon, CO,
USA). After 48 hr the medium was changed and the cells were grown to confluence. Knockout was confirmed by immunoblotting.
Immunoblotting and chemical fractionation
Cell lysates were obtained by lysing washed cells with RIPA buffer (50 mM Tris HCl pH 7.5, 150 mM NaCl, 1% NP40, 0.5% Sodium
deoxycholate monohydrate, 0.1%SDS, 2.5 U Benzonase, 200 mMMn2+) containing protease inhibitor cocktail and incubated head-
over tail at 4C for 60min. Cell lysateswere clarified by centrifugation and the protein concentration was quantified using the Bradford
assay. Lysates were separated using SDS-PAGE and transferred onto nitrocellulose (0.2 mM) or PVFF membranes (0.45 mM). Mem-
branes were blocked in 5%BSA-TBST. Membranes were reacted with primary antibodies, washed four times, 5 min each with 0.1%
Tween-20 (pH 7.6), and subsequently incubated with peroxidase-conjugated secondary antibodies. Chemiluminescence was per-
formed using Clarity Western ECL Substrate. For cellular fractionation experiments, U2-OS cells were chemically fractioned using a
subcellular protein fractionation kit (Thermo Fisher Scientific, USA). For that, cells were harvested with trypsin-EDTA, centrifuged at
500g for 5min andwashed with ice-cold PBS. After adding CEB buffer to the cell pellet, the tube was incubated at 4C for 10min with
gentle mixing. Following centrifugation at 500g for 5 min the supernatant (cytoplasmic extract) was transferred to clean pre-chilled
tube on ice. Next, MEB buffer was added to the pellet, the tube briefly vortexed and incubated at 4C for 10 min with gentle mixing.
The tube was then centrifuged at 3000g for 5 min and the supernatant (membrane extract) transferred to a clean pre-chilled tube on
ice. NEB buffer was added to the pellet, vortexed on the highest setting for 15 s. Following an incubation at 4C for 30 min with gentle
mixing, the tube was centrifuged at 5000g for 5 min and the supernatant (nuclear extract) transferred to a clean pre-chilled tube on
ice. Lastly, room temperature NEB buffer containing Micrococcal Nuclease and CaCl2 was added to the pellet, vortexed for 15 s and
incubated at room temperature for 15 min. After incubation, the tube was centrifuged at 16,000g and the supernatant (chromatin-
bound nuclear extract) transferred to a clean pre-chilled tube on ice.
Cell viability measurement
Cell lines were plated into 96-well plates at densities of 5000-10000 cells/well. 24 hr later, cells were treated with various doses of
genotoxic chemicals for 96 hr. After the incubation, room-temperature CellTiter-Glo Reagent (Promega, USA) was added 1:1 to
each well and the plates were incubated at room temperature for 10 min. Luminescence was measured with the Tecan Infinite
M1000 Pro (Tecan, Ma¨nnedorf, CHE) and normalized against control cells treated with vehicle solution.
Clonogenic survival assay
U2-OS cells were plated in triplicate at densities of 100–3000 cells per 60mmplate and incubated for 24 hr before exposure to various
NCS doses. Twoweeks later cell colonies were fixed and stainedwith 0.2% crystal violet in 50%ethanol and counted under a dissec-
tion microscope.
Cleaved caspase-3 measurement
U2-OS cells were harvested and washed with 1 mL of ice-cold PBS. Fixation was performed by adding 1 mL of ice-cold 100%meth-
anol slowly while gently vortexing. After 10 min, cells were washed three times with 1 mL of PBS + 0.5% BSA, and anti-cleaved cas-
pase-3 (Asp175) was added. Cells were incubated for 2 hr at room-temperature, washed and incubated with secondary Alexa Fluor
488 in the dark for 1hr andwashed three timeswith 1mL of PBS + 0.5%BSA. Sortingwas performed using aBeckmanCoulter Gallios
flow cytometer at 50.000 events/ sample and analyzed with the software Kaluza (Beckman Coulter).
Comet assay
Cells were treatedwith DNAdamaging agents, harvested, and the comet procedurewas applied using the CometAssay experimental
system (Trevigen). For that, cells were mixed with low-melting agarose and the cell suspension was overlaid on microscope slides.
Cell lysis was carried out within the agarose. After lysis, electrophoresis of the DNA trapped in the agarose was performed at 1 V/cm
for 30min. After staining the slides with SYBRGreen dye for 10min, images of 100 randomly selected cells per sample were captured
using a Nikon eclipse 55i fluorescent microscope and digital fluorescent images were obtained by using the NIS-elements AR soft-
ware. The relative length and intensity of DNA tails relative to heads is proportional to the amount of DNA damage in individual nuclei.e7 Cell 176, 505–519.e1–e10, January 24, 2019
These parameters weremeasured observer-independent and in an unbiased fashion by tail moment quantificationwith TriTek Comet
Score software (TriTek Corp., Sumerduck, VA). Exemplary images of single cells from comet slide samples were obtained post
analysis.
DSB repair pathway assays
U2-OS cells bearing a single-copy integration of the reporters DR-GFP (Gene conversion), or SSR (NHEJ:HR) were used to analyze
the different DSB repair pathways (Lo´pez-Saavedra et al., 2016). In both cases, 4.000 cells were plated in 96-well plates. One day
after seeding, cells were transfected with the indicated siRNA or infected with retroviral particles carrying the indicated plasmids.
The medium was changed after 6-8 hr. The following day, cells were infected with a lentivirus harboring I-SceI and labeled with
BFP at a multiplicity-of-infection of 10 (Lo´pez-Saavedra et al., 2016). After 24 hr, cells were washed with fresh medium and main-
tained during an additional 24 hr. Cells were then fixed with 4% paraformaldehyde, stained with Hoechst 33,432, and washed
with PBS before visualization with a fluorescent microscope for blue, and in the case of SSR, green and red fluorescence. The repair
frequency was calculated as the percentage of blue cells expressing GFP for the DR-GFP. For the NHEJ:HR balance, the ratio be-
tween green versus red cells in each condition was calculated. To facilitate the comparison between experiments, this ratio was
normalized with siRNA or an empty vector control. Conditions that skewed the balance toward increased NHEJ repair resulted in
a fold increase above 1. In contrast, a net decrease of this ratio (for example, values below 1) represented an imbalance of SSR to-
ward HRR. Data represent a minimum of four sets of triplicate experiments. Statistical significance was determined using the paired
sample t test.
Single Molecule Analysis of Resection Tracks
Single Molecule Analysis of Resection Tracks (SMART) was performed as previously described (Cruz-Garcı´a et al., 2014). For that
purpose, U2-OS cells transfected with siRNA against UBQLN4, a control siRNA, UBQLN4.FLAG, UBQLN4.S318A.FLAG or
empty-vector FLAG construct were cultured in the presence of 10mM bromodeoxyuridine (BrdU) for 24 hr, irradiated with 10 Gy
of IR and harvested 1 hr later. Cells were embedded in low-melting agarose and in-gel DNA extraction followed. To stretch the
DNA fibers, silanized coverslips were dipped into the DNA solution for 15min and pulled out at constant speed (250mm/s). Coverslips
were baked for 2 h at 60C and incubated without denaturation with an anti-BrdU mouse monoclonal antibody. After washing with
PBS, coverslips were incubated with a secondary antibody. The coverslips were mounted with ProLong Gold Antifade Reagent
(Molecular Probes, Oregon, USA) and stored at 20C. DNA fibers were observed using a Nikon NI-E microscope under a PLAN
FLOUR40 3 /0.75 PHL DLL objective. The images were recorded and processed using NIS ELEMENTS Nikon software. For each
experiment, at least 200 DNA fibers were analyzed, and the length of DNA fibers was measured using Adobe Photoshop CS4
Extended version 11.0 (Adobe Systems Incorporated). Experiments were repeated independently four times. Statistical significance
in these experiments was determined with the paired Student’s t test.
Laser microirradiation and imaging of cells
U2-OS cells expressing ectopic, GFP-tagged proteins were plated on glass bottom dishes (MatTek, Ashland, MA) and pre-sensitized
with 10 mMBrdU for 48 hr. The dishes were transferred into amicroscope top-stage incubator equipped with a control system for gas
mixture and humidity (Okolab, Ottaviani, Italy). DNA damage was induced on a Leica TCS SP8 confocal microscope (Leica Micro-
systems, Wetzlar, Germany) using a 405 nm diode laser focused through an HC PL APO 63X, 1.4-numerical aperture oil immersion
objective (8% laser power, scan speed 650 msec, 40 scans). Images were acquired using the same system.
Relocalization of endogenous proteins to sites of laser-induced DNA damage was followed by immunostaining. DNA damage was
induced using two-photon-based micro-irradiation obtained from an 800 nm laser beam in an LSM 510 Meta confocal microscope
(Carl Zeiss, Jena, Germany). The microscope was equipped with a Spectral-Physics Mai-Tai (Deep-See) multi-photon laser system
focused through a 633 1.25 numerical aperture oil immersion objective. Microirradiation was carried out at 8% laser power and scan
speed of 1.61 msec, with 40 repetitions at zoom3 1. A Leica TCS SP8 confocal microscope was used for imaging. In order to visualize
UBQLN4 and 53BP1 laser stripes, cells were washed with PBS and incubated for 3 min at room temperature with CSK buffer con-
taining 10 mM PIPES, pH 7.0, 100 mM NaCl, 300 mM sucrose, 3 mMMgCl2, and 0.7% Triton X-100. The cells were then washed in
PBS and incubated for another 3 min in CSK buffer supplemented with 0.3 mg/ml RNase A. The above described immunofluores-
cence protocol was then followed.
Immunostaining and fluorescence measurements
HDFs were seeded onto 96 well plates for immunofluorescence assays. For RAD51 stainings, cells were additionally pre-extracted in
sucrose buffer (25mMHEPES pH 7.5, 50mMNaCl, 1mMEDTA, 3mMMgCl2,300mMSucrose, 0.5%Triton-X) for 2min on ice. Cells
were fixed for 10 minutes in room temperature with 4% Paraformaldehyde, followed by three washes with ice-cold 1x PBS. Subse-
quently, the cells were blocked for 60 min at room temperature in PBS containing 5% normal goat serum (NGS), 2% bovine serum
albumin and 0.01% Triton X-100. Incubation with the primary antibody was performed over night at 4C. Incubation with the second-
ary antibody was performed for 1 h at room temperature. Analysis was performed as described in ‘‘High-content screening micro-
scopy.’’ In contrast, U2-OS cells were fixed and stained on regular coverslips. Cleaved caspase 3 intensity and nuclear foci of gH2AX
in U2-OS cells were quantified using ImageJ software (with the PZfociEZ plugin for gH2AX nuclear foci).Cell 176, 505–519.e1–e10, January 24, 2019 e8
High-content screening microscopy
High-content screening (HCS) microscopy was performed on HDFs using a Thermo Fisher Cellomics ArrayScan XTI with LED light
source. Images of 11043 1104 pixels were acquired with a 20x objective (Zeiss) and analyzed using the Cellomics software package
(Colocalization V.4 Bioapplication). Images were background corrected (3D surface fitting) and DAPI stained cell nuclei were iden-
tified according to the object selection parameters size: 100–1500 mm2, ratio of perimeter squared to 4p area: 1–2, length-to-width
ratio: 1–5, average intensity: 400–4000, total intensity: 43 106–23 107. Foci of gH2AX, MRE11, RPA70, RAD51 and Ubiquitin inten-
sities were quantified within the nuclear region at another excitation wavelength (485 ± 20 nm or 650 ± 20nm). Object selection
parameters for foci were size: 0.1–10 mm2, ratio of perimeter squared to 4p area: 1–5, length-to-width ratio: 1–5, average intensity:
500–10000, total intensity: 300–2 3 106. To determine the cell cycle stage, we analyzed the distribution of the total DAPI intensity
using a customR script. Four thresholds were adjustedmanually to gate cells in 2N (G0/G1), 2-4N (S), and 4N (G2/M) stages, respec-
tively. Cells in the G0/G1 phases possess a normal diploid DNA content (2N) whereas cells in G2/M contain exactly twice this amount
(4N). As DNA is synthesized during S-phase, cells are found with a DNA content ranging between 2N and 4N. The gates were then
applied to evaluate the mean number of foci in cells of the respective cell cycle stage. Single cell data were further processed and
plotted using R packages. High content screening kinetic experiments were analyzed with R using ordinary two-way ANOVA.
HCS microscopy results are means ± standard deviation; n = 3-4 wells; > 2000 cells/well; two-way ANOVA with Bonferroni’s test.
*p < 0.05; **p < 0.01; ***p < 0.001.
Immunoprecipitation
For GFP-Trap and FLAG-IP experiments, 293FT cells were transfected with respective plasmids, treated and harvested. Cells were
then incubated in lysis buffer (150 mM NaCl, 50 mM Tris HCl pH 7.5, 2 mMMgCl2, 1% NP40 and EDTA-free protease inhibitor cock-
tail) for 60min with rotation at 4C. For the identification of ubiquitin-dependencies 10mMN-Ethylmaleimide (NEM) was added to the
lysis buffer. The resultant cell lysates were pre-cleared at 15.000 g at 4C for 20 min. Lysates were incubated with GFP-Trap agarose
beads or FLAG-M2 agarose beads at 4C for 3 hr. The resulting complexes were washed with wash buffer (150mMNaCl, 50mM Tris
HCl pH 7.5, 0.5% NP40 and complete protease inhibitor cocktail) and analyzed by SDS-PAGE. In the case of HIS immunoprecipi-
tations, Ni-NTA magnetic beads were added to lysates also containing 15 mM Imidazole, 5 mMTris-(2-carboxyethyl)-phosphin
(TCEP) and incubated overnight at 4C with gentle agitation. Beads were washed 5 times with IP wash buffer (20 mM HEPES
pH 7.9, 300 mM NaCl, 10% Glycerol, 0.1% NP-40, 5mM TCEP, 15 mM Imidazole, 10mM NEM) and eluted in elution buffer
(20 mM HEPES pH 7.9, 300 mM NaCl, 10% Glycerol, 0.1% NP-40, 5 mM TCEP, 200 mM Imidazole). In the case of USP2 treatment,
20 ml USP2 buffer (35 mM HEPES pH 7.9, 75 mM NaCl, 1 mM DTT) and 50 mMUSP2 were added to the sample and the sample was
incubated for 30 min at 37C with gentle agitation.
LC-MS/MS phosphorylation analysis
Cell lysates were precipitated with acetone and resuspended in 8 M Urea. After reduction with DTT and carbamidomethylation with
IAA, proteins were digested overnight at 37C, using the proteases LysC (Wako) and, after dilution with 50 mMpotassium phosphate
buffer pH 5.8, trypsin (Promega) and GluC (Promega). Samples were desalted using SepPak C18 cartridges (Waters) and phosphor-
ylated peptides enriched with the High-Select TiO2 Phosphopeptide Enrichment Kit (Thermo Fisher). Proteomic analysis was
performed using an Easy nLC 1200 UHPLC coupled to a QExactive HF-X mass spectrometer (Thermo Fisher). Peptides were resus-
pended in Solvent A (0.1% FA), picked up with an autosampler and loaded onto in-house made 50 cm fused silica columns (internal
diameter (I.D.) 75 mm, C18 1.7 mm, Dr. Maisch beads) at a flow rate of 1.5 mL/min. A 90min segmented gradient of 4%–55%Solvent B
(80%ACN in 0.1%FA) over 81min and 55%–95%Solvent B over 9min at a flow rate of 250 nL/minwas used to elute peptides. Eluted
peptides were sprayed into the heated transfer capillary of the mass spectrometer using a nano-electrospray ion source (Thermo
Fisher Scientific). The mass spectrometer was operated in a data-dependent mode, where the Orbitrap acquired full MS scans
(350-1650 m/z) at a resolution (R) of 60,000 with an automated gain control (AGC) target of 3 3 106 ions collected within 20 ms.
The dynamic exclusion time was set to 20 s. From the full MS scan, the 15 most intense peaks (z R 2) were fragmented in the
high-energy collision-induced dissociation (HCD) cell. The HCD normalized collision energy was set to 28%. LC-MS/MS scans
with an ion target of 1.5 3 105 ions were acquired with R = 30,000, with a maximal injection time of 54 ms and an isolation width
of 1.3 m/z. The raw files were processed using MaxQuant software (version 1.5.3.8) and its implemented viewer and Andromeda
search engine (Cox et al., 2011). Parameters were set to default values and Phospho (STY) was added as variable modification. In-
tensities were scaled to mean of zero and unit variance for separate measurements. Graphs were generated and two-sided t test.
Histological analysis
Formalin-fixed paraffin-embedded (FFPE) nevus and melanoma samples were cut into 4mm thick sections and mounted on slides.
After UBQLN4 staining, samples were assessed and the H-score calculated.
Measurement of C. elegans HRR efficiency
Worms were synchronized at late L4 stage by picking and were kept for 24 hr at 20C until reaching adulthood. For each condition, 5
adult worms were transferred to 35-mm NGM plates seeded with a drop of OP50 and allowed to lay eggs for a time period of 2 hr at
20C. Animals were then removed from plates and eggs were immediately irradiated with 0, 20 or 40 Gy of g-irradiation. 24 hr later,e9 Cell 176, 505–519.e1–e10, January 24, 2019
numbers of hatched and non-hatched eggs were counted and percentages of embryonic survival were calculated. Each experiment
was performed in biological triplicates.
C. elegans immunofluorescence staining
Wt and ubql-1(tm1574) mutants were synchronized at L4 larval stage by picking and kept at 20C. 24 hr later worms were either
exposed to 90 Gy of g-irradiation using a BIOBEAM 8000 with Cs137 radionucleotide source, or were left untreated to serve as nega-
tive controls. Worms were kept another 24 hr at 20C before being dissected with syringe needles to expose germlines. Tissues were
fixed for 5 min with 4% paraformaldehyde solution on adhesive HistoBond+ slides (Paul Marienfeld GmbH & Co. KG) before freeze
cracking on dry ice. Slides were subsequently fixed for 1 min in ice-cold methanol at 20C and washed 3x in PBS-T followed by a
30min blocking step with 10%donkey serum in PBS-T. For detection of ubiquitinylated conjugates tissues were incubated overnight
at 4C with monoclonal FK2 antibody (Merck Millipore; Dilution: 1:500 in 10% donkey serum in PBS-T). The next day, slides were
washed 3x in PBS-T and exposed to secondary antibody (AlexaFluor 488 Donkey anti-Mouse IgG; Dilution: 1:500 in 10% donkey
serum in PBS-T) for 2 hr at room-temperature in the dark. After 3 final washes in PBS-T, slides were mounted with a drop of DAPI
Fluoromount-G (SouthernBiotech) and sealed with nailpolish. Images of five individual germlines per condition were taken using
a Zeiss Meta 710 confocal microsope. Images were subsequently processed and analyzed using the ImageJ software package.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed using the GraphPad Prism software package. The type of statistical analyses, parameters and
number of replicates are indicated for each experiment in the figure legends. For all tests, p value significance was defined as follows:
not significant (n.s.) p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001.
DATA AND SOFTWARE AVAILABILITY
Themass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository
with the dataset identifier PXD011488. High-content screening (HCS) microscopy raw data has been deposited to the Mendeley re-
pository under https://doi.org/10.17632/gz4xvwbvhs.1.Cell 176, 505–519.e1–e10, January 24, 2019 e10
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Figure S1. Homozygous c.976C > T Mutation in the UBQLN4 Gene Leads to UBQLN4 Deficiency Syndrome, Related to Figures 1 and 2
(A) Number of variants remaining after each filtering step.
(B) Genomic sequencing of lymphocyte DNA obtained from a healthy control, patient B-IV-3, and carriers B-III-2 and B-III-3. The arrow indicates the location of
the c.976C > T mutation.
(C) Lysates of WT and DMFs derived from patient B-IV-3, subjected to immunoblotting with an n-terminal anti-UBQLN4 antibody. The asterisks mark an un-
specific band.
(D) Normalized UBQLN4 transcriptome sequencing coverage for cell lines derived from patients A-IV-5 and B-IV-3, the carrier B-III-2 and wt controls (WT_1 and
WT_2). Gene expression of UBQLN4 is represented by FPKM values (fragments per kilobase of exon per million fragments mapped).
(E) High throughput screen for DDR factors in the ubiquitin arena (Baranes-Bachar et al., 2018). Human Tert-immortalized fibroblasts seeded in 384-microwell
plates were reverse-transfected with siRNAs representing 1591 siRNA pools targeting mRNAs of various proteins that are involved in protein ubiquitylation and
the ubiquitin-proteasome system. 72hrs later, cells were treated with 100 ng/ml NCS, and 24 hr later fixed and stained with an antibody against phospho-KAP-1.
(F) Quantitative data from 3 experimental repeats were normalized and plotted as fold change from median in respect to p value. p values were converted
directly from Z-scores and were not corrected for multiple testing, as UBQLN4 was specifically looked at in an exploratory setting. Upward triangles indicate
p values < 0.0001; tilted triangles indicate p values < 0.0001 and fold change from the median > 1.5.
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Figure S2. Images Displaying Patients A-IV-4 and B-IV-3, Related to Figure 1
(A-H) Patient A-IV-4 shortly after birth with low-set and posteriorly rotated ears, right preaxial polydactyly and bilateral simian creases.
(I-K) Patient A-IV-4 at the age of 5 4/12 years presenting with proptosis, prominent nose and micrognathia.
(L-M) Patient A-IV-4 at the age of 11 years presenting with dystrophic habitus, hypertelorism, downward slanting palpebral fissures, proptosis, long nose, small
mouth, feet brachydactyly and hyperpigmented areas.
(N and O) Patient B-IV-3 at the age of 17 months with proptosis, micrognathia and low-set ears.
(P-R) Patient B-IV-3 at the age of 6 years, presenting with hypertelorism, large nose, an underriding and hypoplastic third toe.
(S-W) Patient B-IV-3 at the age of 10 years, with large nose, short philtrum, camptodactyly of fingers III to V, dark nevi on the right foot, dorsal hirsutism, pes
adductus and dystrophic habitus.
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Figure S3. Loss of UBQLN4 Increases Cellular Sensitivity to Genotoxic Agents, Related to Figure 2
(A) Immunoblot displaying the expression level of UBQLN4 of cell lines used in (B-E). The asterisks mark an unspecific band.
(B-E) Intracellular ATPwasmeasured as a surrogate marker for cell viability. Cells with the indicated genotypes were treated with NCS (B), etoposide (C), cisplatin
(D) or HU (E) for 96 hr and ATP levels weremeasured. Dose response curves were generatedwith error bars displaying the standard deviation of themean of three
independent experiments. p values were calculated using the t test with Welch’s correction not assuming equal variance. p < 0.05 (*); p < 0.01 (**); p < 0.001 (***).
(F) Immunoblot depicting UBQLN4 expression levels of cells used in (G).
(G) Clonogenic survival curve of U2-OS cells transduced with two shRNAs directed against UBQLN4 and subsequently treated with various NCS doses.
shControl transduced cells and cells treatedwith ATM inhibitor KU-60019 (ATMi, 5mM) served as negative and positive controls, respectively. Error bars represent
the standard deviation of the mean of n = 3 experiments. p values were calculated using the t test with Welch’s correction not assuming equal variance.
p < 0.05 (*); p < 0.01 (**).
(H) Number of gH2AX nuclear foci in U2-OS cells treated with 50 ng/ml of NCS at the indicated time points. Cells were transduced with control shRNA (shCtrl) or
two shRNAs directed against UBQLN4. Error bars represent the standard deviation of 1000 cells analyzed in 3 independent experiments. Statistical significance
was determined with the paired Student’s t test. p < 0.05 (*).
(I) gH2AX intensity was measured throughout the cell cycle in cells with the indicated genotype following cisplatin treatment. Cell cycle analysis was performed
according to DAPI intensity of the nuclei (< 2N = sub G1; 2N = G1; 2-4N = S; 4N = G2). The percentage of gH2AX positive cells within the cell cycle is indicated.
(J) Automated imaging of identical view fields related to Figures 2I–2M allowed the quantification of the relative number of cells observed at the indicated time
points and treated with the indicated genotoxic agents. Error bars represent SD of the mean for 3 replicate wells analyzed in one experiment. Easch experiment
was carried out twice. Two-way ANOVA with Bonferroni posthoc test, p < 0.05.
(K) Automated imaging of identical view fields of the indicated genotypes allowed the quantification of the relative number of cells observed at the indicated
time points and treated with 250 ng/ml NCS. n = 3 replicate wells analyzed in three experiments, mean ± SD, Two-way ANOVA with Bonferroni posthoc test,
p < 0.05 (*).
(L) Immunoblot displaying the expression level of UBQLN4 of cell lines used in Figures 2N and 2O.
(M) Representative images of neutral comet assays related to Figure 2N of NCS-induced (50 ng/ml) DSBs in U2-OS cells transduced with shControl, two
independent shUBQLN4 and shUBQLN4 knockdown cells complemented with ectopic UBQLN4 cDNA. Scale bar, 10 mm.
(N) Indirect immunofluorescence of MDA-MB-231 UBQLN4-KO cells and wt MDA-MB231 cells with anti-UBQLN4 antibody. Scale bar, 10 mm.
(O) Lysates of MDA-MB-231 UBQLN4-KO cells and wt MDA-MB231 cells immunoblotted with anti-UBQLN4 antibody.
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Figure S4. ATM-Dependent Phosphorylation of UBQLN4 Mediates DSB Repair, Related to Figure 3
(A) Immunoblot of U2-OS cells treated with 500 ng/ml NCS for the indicated time points. Cell lysates were subsequently fractionated for immunoblotting. Histone
H3 served as a positive marker for the chromatin fraction.
(B) Domain diagrams of UBQLN4 mutants.
(C) Recruitment of GFP.UBQLN4DUBA, GFP.UBQLN4DUBL and GFP.UBQLN4.S318A mutant to sites of DNA damage 15 min after damage induction using a
focused laser micro beam. Scale bar, 10 mm.
(D) Immunoblot to demonstrate the detection of S318 UBQLN4 phosphorylation in U2-OS cells using a specific anti-phospho S318 antibody. GFP-tagged
UBQLN4 in wt and S318A mutant versions was ectopically expressed in U2-OS cells. At 1 hr after treatment with 10 Gy of IR, ectopic UBQLN4 was immuno-
precipitated using an anti-GFP antibody, and the immune complexes were blotted with the indicated antibodies. I = Input; UB = Unbound fraction; IP: Bound
fraction. A low-intensity unspecific phosphorylation band is seen in the S318A mutant control IP fraction.
(E) Densitometry analysis of three independent experiments related to (D). Densitometry was quantified by ImageJ of S318-UBQLN4 phosphorylation and
normalized to wt UBQLN4. Error bars display the standard deviation of three independent experiments. UT = untreated; T = treated. p values were calculated
using the t test with Welch’s correction. p < 0.05 (*).
(F) Immunoblot to demonstrate dimerization/polymerization of tagged UBQLN4. GFP-tagged and FLAG-tagged UBQLN4 was ectopically expressed in U2-OS
cells, ectopic UBQLN4 was immunoprecipitated using FLAG beads and the immune complexes were blotted with UBQLN4 antibody. Empty-vector GFP served
as a control.
(G) U2-OS cells transfected with the indicated shRNAs, treated with 10 Gy of IR, and processed for immunoblotting with anti-UBQLN4- and anti-pS318 UBQLN4
antibody at the indicated time points.
(H) Cellular extracts of U2-OS cells were subjected to immunoblotting after treatment with etoposide (Eto), camptothecin (CPT) or hydroxyurea (HU) at the
indicated time points. pS824-KAP1 antibody was used as a positive control.
(I) Densitometry analysis of four independent experiments related to (H). Densitometry was quantified by ImageJ of S318-UBQLN4 phosphorylation and
normalized to wt UBQLN4. Error bars display the standard deviation of four independent experiments. p values were calculated using the t test with Welch’s
correction. p < 0.05 (*);p < 0.01 (**).
(J) U2-OS cells were fractionated (Cyt = cytoplasma; Nuc = nuclear; Chr = chromatin; Mem = membrane) following 1 hr of 500 ng/ml NCS and subjected to
immunoblotting. Anti-Histone H3 antibody served as control for the chromatin fraction.
(K) Densitometry analysis of three independent experiments underlying Figure 3E. Densitometry was quantified by ImageJ of S318-UBQLN4 phosphorylation and
normalized to wt UBQLN4. Error bars display the standard deviation of three independent experiments. p values were calculated using the t test with Welch’s
correction. p < 0.05 (*); p < 0.01 (**).
(L) Selected LC-MS/MS scan of the UBQLN4 peptide with phosphorylated S144 and annotated b- and y-ions. Fragment ions marked with an asterisk (*) result
from loss of the phospho- group. Inset top right: LC-MS/MS measured intensities of the phosphorylated S144 site after indicated treatments.
(M) Immunoblot depicting the expression levels of endogenous and ectopic UBQLN4 in cells used for clonogenic survival assays in Figure 3G.
(N) Immunoblot depicting the expression levels of endogenous and ectopic UBQLN4 in cells used for clonogenic survival assays in (O).
(O) Clonogenic survival curve of U2-OS cells transduced with shRNA directed against UBQLN4 (targeting 30UTR) andmutant forms of UBQLN4 and subsequently
treated with various NCS doses. Error bars represent the standard deviation of the mean of n = 3 experiments. p values were calculated using the t test with
Welch’s correction not assuming equal variance. p < 0.05 (*).
(P) Immunoblot displaying the expression level of UBQLN4 of cell lines used in Figure 3H.
(Q) Representative images of neutral comet assays of NCS-induced (50 ng/ml) DSBs in U2-OS cells transduced with either shControl or shUBQLN4 and
complemented with UBQLN4-wt, S318A mutant or S318D mutant plasmid related to Figure 3H. Scale bar, 10 mm.
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Figure S5. Loss of UBQLN4 Leads to Increased HRR and Retention of MRE11, Related to Figures 4 and 5
(A) Immunoblot of MRE11 that co-precipitated with GFP or UBQLN4.GFP using GFP-Trap beads. Immune complexes were obtained from lysates of U2-OS cells
mock-treated or treated with NCS (500 ng/ml, 1 hr).
(B) Schematic representation of the SeeSaw 2.0 reporter. A GFPORF is flanked by two truncated parts of an RFPORF (RF and FP) sharing 302 bp of homologous
sequence. Two I-SceI target sites in opposite orientation are present at the 30 end of the GFP ORF. After generation of a DSB by ectopic I-SceI endonuclease, the
DSB may be repaired via NHEJ and cells will retain GFP expression, or the DSB may be repaired via HRR, creating a functional RFP ORF.
(C) Schematic representation of the DR-GFP reporter. DR-GFP is composed of two differentially mutated GFP genes: the upstream repeat contains the
recognition site for the I-SceI endonuclease and the downstream repeat is a 50 and 30 truncatedGFP fragment. Transient expression of I-SceI leads to aDSB in the
upstream GFP gene; DSB repair by HRR results in GFP positive cells.
(D and E) A total number of 2000 cells/well was counted and the number of RPA70 nuclear foci (D) and 53BP1 nuclear foci (E) were quantified according to cell
cycle stage and normalized to respective gH2AX foci count. High content screening kinetic experiments were analyzed with R using ordinary two-way ANOVA.
Bonferroni’s post hoc analysis was applied to determine p values of selected pairs defined in a contrast matrix using the R library multcomp. Error bars represent
the standard deviation of the mean of 3 replicate wells analyzed in one experiment. Each experiment was carried out twice. p < 0.05 (*); p < 0.01 (**); p < 0.001 (***).
(F) DMFs with the indicated genotypes were pulse-chased with cycloheximide (100 mg/ml) and treated with 500 ng/ml of NCS. Cells were then fractioned at the
indicated time points and the chromatin fraction was immunoblotted against MRE11. Histone H3 served as a marker for the chromatin fraction.
(G) Quantification of 6 independent experiments performed in (F). Paired t test was used for statistical analysis. p < 0.05 (*).
(H) Cell cycle analysis of either untreated or NCS-treated (500 ng/ml) cells with indicated genotypes between 0 and 48 hr. The distributions shown were derived
from 5 independent experiments (Rep1-5). Of note, the rescue (UBQLN4wt-complemented patient cells) was performed in 3 of these experiments.
(I) Cells with the indicated genotypes were pre-treated with MG132 (10mM) 1 hr prior to NCS (500 ng/ml) treatment and stained for nuclear foci of ubiquitin (Ub) at
the indicated time points. 2500 cells/well were counted at each time point and Ub fluorescence was quantified using high content screening kinetic experiments,
which were analyzed with R using ordinary two-way ANOVA. Bonferroni’s post hoc analysis was applied to determine p values of selected pairs defined in a
contrast matrix using the R library multcomp. Error bars represent the standard deviation of the mean for 3 replicate wells analyzed in three independent ex-
periments. Not significant (n.s.) p > 0.05.
(J) Immunoblot of FLAG.MRE11 or empty-vector FLAG that co-precipitated with His-Ubiquitin (Ub) using Ni-NTA metal beads in whole cell lysate. Immune
complexes were obtained from lysates of HEK293FT cells mock-treated or treated with NCS (500 ng/ml, 1 hr).
(K) Immunoblot of FLAG.MRE11 that co-precipitated with GFP.UBQLN4 or empty vector.GFP using GFP-beads. Immune complexes were obtained from lysates
of HEK293FT cells treated with NCS (500 ng/ml, 1 hr). USP2 (50 nM) was added for 30 min at 37C to the agarose-beads after washing of beads was completed.
(L) Representative images of MRE11 nuclear staining and ubiquitin (Ub) nuclear staining obtained 24 hr after NCS (500 ng/ml) +/ MG132 treatment using
quantitative HCS microscopy. DAPI stained cell nuclei were automatically identified and assigned to a mask. Scale bars, 100 mm.
(M and N) Cells with the indicated genotypes were mock- or pre-treated with MG132 (10mM) 1 h prior to NCS (500 ng/ml) treatment and stained for nuclear
intensity of ubiquitin (Ub) (M) and nuclear MRE11 intensity (N) at the indicated time points. 2500 cells/well were counted at each time point and Ub and MRE11
nuclear fluorescence was quantified using high content screening kinetic experiments. Error bars represent the standard deviation of the mean for 3 replicate
wells analyzed in three independent experiments. p < 0.05 (*).
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Figure S6. High-Level UBQLN4 Expression Is Associated with Aggressive Tumors that Display an Actionable PARP1 Inhibitor Sensitivity,
Related to Figure 6
(A) 498 neuroblastoma cases where divided into quartiles according to the expression levels ofUBQLN4: high (125 patients); intermediate (117 patients); low (128
patients) and very low (128 patients) expression. Kaplan–Meier curves show Event-free survival in all four subgroups.
(legend continued on next page)
(B–D) Overall Survival curve in ovarian cancer (n = 1,816, (B), lung adenocarcinoma (n = 2,437, (C) and breast cancer (n = 5,143, (D) according to either high or low
UBQLN4 mRNA expression levels. The analysis was based on publicly available datasets (Sza´sz et al., 2016).
(E) Disease Free Survival in malignant melanoma according to high or low UBQLN4 mRNA expression levels (mRNA z-scoreR 2 and% 2 or amplified).
(F) Overall Survival in malignant melanoma according to high or low UBQLN4 mRNA expression levels.
(G) Disease Free Survival in metastatic malignant melanoma according to high or low UBQLN4 mRNA expression levels.
(H) Overall Survival in metastatic malignant melanoma according to high or low UBQLN4 mRNA expression levels. The analysis of E-H was performed on the
TCGA dataset.
(I) Representative images of immunohistochemistry performed with an anti-UBQLN4 antibody in nevus, primary melanoma (PRM), lymph node metastasis
melanoma (LNM), and distant organ metastasis melanoma (DOM). Scale bars, 50 mm.
(J) Quantification and comparison of UBQLN4 expression utilizing H-score staining of nevus (n = 5) and metastatic tumor samples (LNM and DOM; n = 20). Error
bars represent the standard deviation. Unpaired t test was used for statistical analysis. p < 0.05 (*).
(K) Intracellular ATP was measured as a surrogate marker for cell viability. U2-OS cells were transduced with either empty.GFP or UBQLN4.GFP and treated with
the PARP1 inhibitor olaparib for 96 hr, before ATP levels weremeasured using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Germany). Error bars
represent the standard deviation of the mean of 3 replicate wells analyzed in three independent experiments. p values were calculated using the t test with
Welch’s correction not assuming equal variance. p < 0.05 (*).
(L) Immunoblot depicting the level of endogenous UBQLN4 in neuroblastoma cell lines GIMEN and SY5Y.
(M) Cellular viability was assessed in neuroblastoma cell lines GIMEN and SY5Y after treatment with the PARP1 inhibitor olaparib for 96 hr. Error bars represent
the standard deviation of the mean of 3 replicate wells analyzed in three independent experiments. p values were calculated using the t test with Welch’s
correction not assuming equal variance. p < 0.05 (*); p < 0.01 (**); p < 0.001 (***).
(N) Immunoblot depicting the level of UBQLN4 in neuroblastoma cell line SY5Y transduced with either shCtrl or two independent shRNA’s targeting UBQLN4.
(O) Immunoblot depicting the level of UBQLN4 in neuroblastoma cell line GIMEN transduced with either empty-vector FLAG plasmid or FLAG-tagged UBQLN4.
(P) Immunoblot depicting the level of endogenous UBQLN4 in neuroblastoma cell lines SKNDZ and NMB.
(Q) Cellular viability was assessed in neuroblastoma cell lines SKNDZ andNMB after treatment with the PARP1 inhibitor olaparib for 96 hr. Error bars represent the
standard deviation of the mean of 3 replicate wells analyzed in three independent experiments. p values were calculated using the t test with Welch’s correction
not assuming equal variance. p < 0.05 (*).
